# THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19

Binh T. Ngo, M.D.1,2,*
binhngo@medmail.usc.edu

Paul Marik, M.D., F.C.C.P., F.C.C.M.
Eastern Virginia Medical School|
Department of Internal Medicine|
Chief, Pulmonary and Critical Care Medicine|
825 Fairfax Ave, Rm 575, Norfolk, VA 23507|
marikpe@evms.edu

Pierre Kory, M.D., M.P.A
Pulmonary and Critical Care Medicine
Aurora St. Luke's Medical Center
Milwaukee, Wisconsin .
pierrekory@icloud.com

Leland Shapiro, M.D.
Rocky Mountain Regional Veterans Affairs Medical Center in Aurora, CO and
University of Colorado Anschutz Medical Campus in Aurora, CO
Supported by The Emily Foundation in Boston, MA
lelandshapiro@cuanschutz.edu

Raphael Thomadsen, P.h.D.
Washington University in St. Louis
thomadsen@wustl.edu

Jose Iglesias, D.O., F.A.S.N.
Jersey Shore University Medical Center, Neptune NJ, Hackensack Meridian School of Medicine at Seton Hall
Jiglesias23@gmail.com

Stephen Ditmore, B.A.
Parkchester Times
stephen.ditmore@gmail.com

Marc Rendell, M.D.2,*
The Rose Salter Medical Research Foundation
Newport Coast, CA 92657
rendell@asndi.com

Daniel Griffin, M.D., Ph.D.
ProHEALTH, an OPTUM Company
Columbia University
College of Physicians and Surgeons
Email: danielgriffinmd@gmail.com

Joseph Varon, M.D., FACP, FCCP, FCCM, FRSM
United Memorial Medical Center
University of Texas School of Medicine
Houston, Texas, USA
joevaron@roamer.net

Michael Dubé, M.D.1
mdube@med.usc.edu

Neha Nanda, M.D.1
Neha.nanda@med.usc.edu

Gino In, M.D., M.P.H.1
Gino.In@med.usc.edu

Daniel Arkfeld,M.D. 1
arkfeld@med.usc.edu

Preet Chaudhary, M.D.1
Preet.chaudhary@med.usc.edu

Vito M. Campese, M.D. 1
campese@med.usc.edu

Diana L. Hanna, M.D. 1
Diana.Hanna@medmail.usc.edu

David E. Sawcer, M.D. Ph.D.1
David.sawcer@medmail.usc.edu

Glenn Ehresmann, M.D.1
Glenn.ehresmann@medmail.usc.edu

David Peng, M.D., M.P.H.1
David.Peng@medmail.usc.edu

Miroslaw Smogorewski, M.D.1
smogorze@med.usc.edu

April Armstrong, M.D., M.P.H.1
April.armstrong@medmail.usc.edu

Rajkumar Dasgupta, M.D.1
"Dasgupta, Rajkumar" <rdasgupt@med.usc.edu>

Fred Sattler, M.D.1
fsattler@usc.edu

Cristina Mussini, M.D.
University of Modena and Reggio Emilia in Italy
Cristina.mussini@unimore.it

Oriol Mitja, Ph.D.
Hospital Universitari Germans Trias i Pujol
Badalona, Spain
omitja@flsida.org

Vicente Soriano, M.D. Ph.D.
UNIR Health Sciences School & Medical Center
C/ Almansa 101
Madrid 28040, Spain
Vicente.soriano@unir.net

Nicolas Peschanski, M.D., Ph.D
UniversityHospital of Rennes
Rennes, France
nicolas.peschanski@chu-rennes.fr

Gilles Hayem, M.D.
Hôpital Paris Saint-. Joseph, 75014
Paris, France.
ghayem@ghpsj.fr

Marco Confalonieri, M.D.
Azienda Ospedaliero-Universitaria di Trieste
Trieste, Italia
marco.confalonieri@asugi.sanita.fvg.it

Maria Carmela Piccirillo, M.D.
Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale
Napoli, Italia
m.piccirillo@istitutotumori.na.it

Antonio Lobo-Ferreira, M.D., Ph.D.
Unidade de Investigação Cardiovascular (UniC), Faculdade de Medicina
da Universidade do Porto, Centro Hospitalar Universitário de São João,
Porto, and Hospital Rainha Santa Isabel, Marco de Canaveses, Portugal
Aloboferreira@gmail.com

Iraldo Bello Rivero M.Sc., Ph.D.
Department of Clinical Investigations
Center for Genetic Engineering and Biotechnology,
Ave 31 e/ 158 and 190. Cubanacan, Playa, 10600

Havana, Cuba.
iraldo.bello@cigb.edu.cu

Eivind H. Vinjevoll, M.D.
Volda Hospital HMR, Norway.
Eivind.vinjevoll@gmail.com

Ivan FN Hung, MBChB, M.D., MRCP, FRCP*3
Li Ka Shing Faculty of Medicine
University of Hong Kong
Ivanhung@hku.hk

1 From the Keck Medical School of USC
2 From the Rose Salter Medical Research Foundation
3 Senior author
* Corresponding author

# ABSTRACT

**BACKGROUND.** The spread of COVID-19 from Wuhan China, has been alarmingly rapid. Epidemiologic techniques succeeded in containing the disease in China, but efforts have not been as successful in the rest of the World, with a total of 29,155,581 confirmed cases of COVID-19, including 926,544 deaths worldwide as of September 15, 2020. Projections are for continued new infections and

deaths if no effective therapeutic interventions can be initiated over the next several months. We performed a systematic review to determine the potential time course for development of treatments and vaccines, focusing on availability now and continuing in the last half of 2020.

**METHODS** Clinical Trials: We reviewed up-to-date information from several sources to identify potential treatments for COVID-19: The Reagan-Udall Expanded Access Navigator COVID-19 Treatment Hub was used to track the efforts of companies to develop agents. We focused on trials completed as of September 1, 2020 on identified agents We used several different sources: (A) covid-trials.org, then validated results on (B) clinicaltrials.gov and the (C) World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP). We excluded studies which were clearly observational, with no randomization, control, or comparison group. We further set a cutoff of 100 for numbers of subjects, since smaller trial size could lack statistical power to establish superiority of the intervention over the control.

Publications: We searched for published trial results on pubmed.gov and on medRxiv, the preprint server, and used a targeted Google™ search to find announcements of unpublished trial results

## RESULTS

Clinical Trials in Recruitment: As of our cutoff date of April 1, 2020, we found 409 trials meeting our minimum requirement of 100 subjects. The WHO Solidarity megatrial for hospitalized patients was launched in over 100 countries, actively comparing hydroxychloroquine (HCQ), lopanovir/ritonavir (LPV/r) alone and in combination with interferon beta-1, and remdesivir. The LPV/r alone and HCQ arms have already been discontinued. Of these, only 9 were conducted on outpatients. A few vaccine

trials are hoping to complete Phase 3 enrollment by the end of the third quarter 2020, but a prolonged follow-up of patients will likely be required.

Clinical trials Completed: As of September 1, 2020, there were 231 trials reporting completion, Of these, only 59 studies enrolled 100 or more subjects. There were 34 trials in hospitalized patients, 9 directed at outpatients, and 8 prevention studies,

Published Data: As of September 1, 2020 we found 70 publications reporting findings in human studies on 13 classes of drugs and on 6 vaccines. There were 33 randomized placebo or active control studies; the rest were retrospective observational. Only seven publications dealt with outpatient care, the rest all in hospitalized patients.

Available Treatments. At this time, remdesivir and convalescent plasma have been granted emergency use authorization in the U.S.A., solely for hospitalized patients. There is also support for glucocorticoid treatment of the COVID-19 respiratory distress syndrome. No treatments or prophylaxis are offered for outpatients.

CONCLUSION. COVID-19 is propagated primarily by infected ambulatory individuals. There have been no options brought forward for prevention and non-hospital treatment with only a few randomized, controlled outpatient studies expected to yield results in time to impact on the continuing pandemic by the end of 2020. It will be necessary for public health authorities to make hard decisions, with limited data, to prevent the continued spread of the disease. The choices will be hardest when dealing with possible early release of safe and effective vaccines which would, of course, be of greatest benefit to the World's population.

Keywords: Coronavirus, COVID-19, SARS-Cov-2, remdesivir, hydroxychloroquine, favipiravir

# INTRODUCTION

The coronavirus SARS-Cov-2 pandemic spread through the World with extraordinary speed from its origin in December 2019 in Wuhan, China. As of September 15, 2020, there have been  there have been 29,155,581 confirmed cases of COVID-19, including  926,544 deaths worldwide affecting 220 countries and territories (1). This viral and multisystemic illness produces mild or no symptoms in about 80% of infected individuals, however, in about 20% can manifest as pneumonia, which may progress to acute respiratory failure requiring assisted mechanical ventilation in up to 5% of patients (2). Symptomatic COVID-19 exhibits a characteristic sequence of events related to the primary viral attack, manifesting as an influenza-like illness with cough, fever, myalgias and fatigue.  In patients destined for severe disease, within seven to 10 days of onset of symptoms, bilateral multiple lobar and subsegmental areas of consolidation are typically seen on chest computed tomography (CT) (See Figure 1) (3). Pneumonia may rapidly progress to acute respiratory failure with elevated cytokines suggesting an immune reaction as probable cause (4). Additionally, a coagulopathy develops and can affect the lungs and other organs, including triggering cerebrovascular thrombosis (5).

In mainland China, vigorous efforts to contain the spread of COVID-19 by home isolation, closure of business activity, travel bans, and tracking and control of contacts succeeded. As of Sept 15, China has had 90,718 confirmed cases with 4,742 deaths, but the number of new cases declined to very low levels

since April (1). Similar measures contained the epidemic in Korea, Taiwan and in New Zealand (1). In Hong Kong, one of the most densely populated areas in the world, universal masking, immediate hospitalization and early antiviral treatment for all confirmed cases have minimized the number of confirmed COVID-19 cases to 4972 in a 7.5 million population with less than 3% requiring ICU care, and 101 fatalities (6). However, the disease has not been similarly controlled in the rest of the World, particularly the United States (USA) where, despite only a fifth of the population of China, there have been 6,462,078 confirmed cases of COVID-19 with 193,119 deaths as of September 15, 2020 (1). In the USA, as in China, the response to the pandemic was through reduction of person-to-person contact by social distancing. Beginning in early March, social gatherings and meetings ended; schools and businesses were closed along with recreation areas, parks, and beaches. These efforts blunted the spread of the disease, but not with the results achieved in China. Due to economic pressures, epidemiologic containment was relaxed resulting in a significant surge surpassing the original April peak.

Facing the growing crisis in early January, Chinese health authorities began treating patients empirically with agents with demonstrated *in vitro* antiviral activity against coronaviruses and those used durprior outbreaks of SARS 2003, H1N1 influenza of 2009 and MERS 2015 in Asia (7). The medications used included the antimalarial drugs hydroxychloroquine (HCQ) and chloroquine, the human immunodeficiency virus (HIV) protease inhibitor lopanovir-ritanovir (LPV/r), the Russian antiviral umifenovir, and traditional Chinese medical approaches (8). Subsequently, the antimalarials were widely used to treat COVID-19 throughout the world, despite cautions from numerous regulatory bodies. The scientific basis for their use was *in vitro* evidence of an effect on blocking viral endosomal penetration, as

well as a known suppressive benefit on undesirable autoimmune effects (9). Clinical studies thus far have been controversial.

Multiple vaccines are in clinical trials to assess safety and effectiveness, but these studies are unlikely to complete Phase III testing and proceed to mass vaccination until early 2021. In view of the continuing daily increase in new cases and deaths, our goal was to assess the options we have at the present time for release of pharmacologic agents to treat and to prevent COVID-19 while awaiting widespread immunization.

# METHODS

CLINICAL TRIALS: We reviewed up-to-date information from several sources to identify potential treatments for COVID-19: The Reagan-Udall Expanded Access Navigator COVID-19 Treatment Hub was used to track the efforts of companies to develop therapeutic interventions. We searched for investigational trials which had begun active recruitment as of April 1, 2020, reasoning that the timeline to implement treatments in the second half of 2020 would require completion by September 1.We further searched for all trials with reported completed enrollment as of September 1, 2020. We used (A) covid-trials.org, a registry to collate all trials in real time with data pulled from the International Clinical Trials Registry Platform and all major national registries (10).We cross validated information on (B) clinicaltrials.gov the registry of clinical trials information maintained by the United States National

Library of Medicine. We further cross referenced the trials on (C) the World Health Organization's International Clinical Trials Registry Platform (WHO ICTRP).We excluded studies which were clearly observational for treatment purposes, with no randomization, control or comparison group. We further set a cutoff of 100 for numbers of subjects since smaller trial size typically lacks statistical power to enable regulatory approval. For each trial selected, we documented the setting of patient contact, either hospital or outpatient, the type of control procedure, the date the trial was initially registered, and the proposed date of completion of enrollment.

PUBLISHED TRIAL RESULTS: Our search was carried on the week of September 1 2020. We identified all publications on pubmed.gov to find peer reviewed articles and on medRxiv to find preprint reports. We further carried out daily Google™ searches on each potential treatment to find preliminary reports, typically presented as press releases, reviewed by a journalist.

VIRTUAL DISCUSSIONS AMONG CO-AUTHORS: We used the preprint server medRxiv to post a systematic analysis of the development of therapeutic interventions for COVID-19 in order to stimulate discussion of the manuscript and allow widespread “open source” input (11). Successive versions have been posted periodically beginning in late May, 2020 and continuing to date.

# RESULTS

REVIEW OF CURRENT TRIALS: As of our cutoff date of April 1, we identified 781 trials worldwide meeting our review criteria. Approximately half the trials were registered in mainland China, and 103 trials were registered in the U.S.A. There were 553 trials in the recruitment process (SUPPLEMENTARY TABLE 1). We found 409 trials meeting the minimum requirement of 100 subjects which were recruiting as of April 1. The WHO organized a megatrial, appropriately named Solidarity, to assess four separate treatment options in hospitalized patients: (a) Remdesivir, an intravenously administered inhibitor of RNA polymerase; (b) LPV/R; (c) LPV/R plus Interferon β-1a; and (d) HCQ or Chloroquine (12). Completion of enrollment is estimated in the first quarter of 2021. However, the antimalarial and LPV/R drug arms of the Solidarity study were terminated after review suggested no benefit in hospitalized patients.

OTHER TRIALS WITH THE SOLIDARITY AGENTS: In addition to and independent from the Solidarity trial, we found 46 ongoing trials of HCQ, 11 trials of LPV/r and 8 trials of interferons (See SUPPLEMENTARY TABLE 2). There were 21 HCQ trials focused solely on hospitalized patients. Ten HCQ trials focused on prevention of the disease. There were seven HCQ trials conducted on ambulatory patients with diagnosed mild disease.

Two prevention trials with LPV/r are currently enrolling, with earliest enrollment completion in the second quarter of 2020 for one and the third quarter for the other. There is one outpatient active comparison trial with HCQ with proposed enrollment end in the second quarter of 2020. There is one large interferon prevention trial scheduled to complete enrollment in the second quarter of 2020.

ANTIVIRAL AGENTS: SARS-Cov-2 attacks cells by binding of the spike protein to the host cell ACE2 receptor. A specific serine protease TMPRSS2 then activates membrane fusion allowing viral RNA to enter the cell to be replicated with release of multiple virions. Numerous antiviral agents are now in active trials (See SUPPLEMENTARY TABLE 3). In addition to remdesivir, trials are ongoing with favipiravir (FVP), an oral inhibitor of the RNA polymerase, and with umifenovir, a membrane lipid fusion inhibitor with broad antiviral properties and with camostat which is a potent serine protease inhibitor (13,14). A very large, multicenter, prevention trial for hospital workers exposed to COVID-19 in Spain, involves 4000 subjects who will be randomized to emicitrabine/tenofovir, an HIV agent, or to HCQ or to placebo. The trial has planned to meet its enrollment goal by the beginning of the third quarter of 2020.

IMMUNE MODULATORS: Many trials are focusing on inhibitors of IL1 and IL6, as well as other agents currently approved for treatment for rheumatoid arthritis and other autoimmune conditions to suppress the cytokine storm of COVID-19 (See SUPPLEMENTARY TABLE 4). These trials are all directed at severely ill COVID-19 inpatients. There is a large multicenter, placebo-controlled trial of colchicine in non-severely ill outpatients scheduled to enroll 6000 individuals by end of the third quarter of 2020.

## OTHER STUDIES (SUPPLEMENTARY TABLE 5):

CONVALESCENT PLASMA: Convalescent plasma has a long history of use to treat microbial illness, including most recently Ebola virus (15). The FDA has approved an expanded access program for convalescent plasma of COVID-19 patients. In addition, several trials of passive immunization with monoclonal antibodies, based on the same principle, have recently begun.

STEM CELLS: Several trials of mesenchymal stem cells are currently recruiting with one study planning completion of enrollment by the end of the second quarter of 2020.

RENIN ANGIOTENSIN SYSTEM: Angiotensin-converting enzyme 2 is the monocarboxypeptidase highly expressed in alveolar epithelial cells and endothelial cells. This receptor has been identified as the binding site for the SARSCoV-2 virus on epithelial cell for entry, speculating interest that ACE inhibitors or angiotensin receptor blockers might block viral access. There are a number of trials either adding the agents or withdrawing them.

PULMONARY AND RESPIRATORY INTERVENTIONS: These studies are of great interest in managing respiratory failure in COVID-19. There are many ongoing studies of mechanical and extracorporeal oxygenation. There was one ongoing study of hyperbaric oxygenation not due to complete enrollment until the second quarter of 2021.

SUPPLEMENTS: The suggestion that zinc may be a beneficial agent together with HCQ in COVID-19 has generated interest, but there is only one study underway, not including HCQ.

GLUCOCORTICOIDS: Given the potential benefit of glucocorticoids during the hyperinfllammatory phase of COVID-19, a number of studies are trying to determine the best timing to begin steroid use without impairing the response to viremia.

ANTICOAGULANTS: Several studies are focusing on prophylaxis for the COVID-19 hypercoagulable state.

TRADITIONAL CHINESE MEDICATIONS: There were 48 such studies. We did not include them in our search for agents which could be made available in the next 6 months for two reasons. First, these medications are not familiar to clinicians in the rest of the World. Second, the success of epidemiologic containment in China has made it unlikely that many projected trials would achieve enrollment.

VACCINES: The WHO has identified 110 programs to develop a SARS-Cov-2 vaccine. Of these, 12 have reached human trials (See SUPPLEMENTARY TABLE 6). Optimistic observers have suggested that a vaccine could be available by the beginning of 2021. A bold suggestion has been made to allow emergency authorization of favorable vaccine candidates by the fall. An additional approach has been suggested to attempt to stimulate non-specific immunity prior to availability of a COVID-19 vaccine using oral polio vaccine or BCG vaccination (16). There are two large prevention trials underway

in the Netherlands and Australia using BCG vaccine in health care workers. These trials plan conclusion of enrollment, but not until the fourth quarter of 2020.

COMPLETED TRIALS: As of September 1, 2020, there were 231 trials reporting completion. Of these, only 59 studies enrolled 100 or more subjects (SUPPLEMENTARY TABLE 7). Sixteen of these studies were of alternative medications. There were 34 trials in hospitalized patients, 9 directed at outpatients, and 8 prevention studies. Most of the trials completed were in Iran. The HCQ and LPV/r arms of the RECOVERY trial in hospitalized patients in the United Kingdom have ended after preliminary data showed no change in mortality. The NIH has halted its HCQ studies.

PUBLISHED RESULTS ON COVID-19 TRIALS: As of September 15, 2020 we found 70 publications reporting findings in human studies on 13 classes of agents, and on 6 vaccines (See TABLE 1). There were 33 randomized placebo or active controlled studies. The rest were retrospective observational analyses. Only seven publications dealt with outpatient care, the rest all in hospitalized patients.

In the group of antiviral agents, the largest published randomized, controlled trials were with remdesivir. The first multicenter trial conducted at ten hospitals in Hubei, China was halted in April due to lack of recruitment after 237 patients enrolled (17). Remdesivir use was not associated with a difference in time to clinical improvement (hazard ratio 1.23 [95% CI 0.87–1.75], decreased viral load, nor mortality benefit. The largest trial of remdesivir, in 1063 moderate to severely ill patients, was a double blind, randomized placebo controlled study carried out by the National Institute of Arthritis and

Infectious Disease (NIAID) (19). The patients who received remdesivir had a median recovery time of 11 days (95% confidence interval [CI], 9 to 12), as compared with 15 days (95% CI, 13 to 19) for those who received placebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P<0.001). The Kaplan-Meier estimates of mortality by 14 days after randomization were 7.1% with remdesivir and 11.9% with placebo (hazard ratio for death, 0.70; 95% CI, 0.47 to 1.04). On the basis of this trial, the Food and Drug Administration (FDA) issued an emergency authorization for use of remdesivir for COVID-19 hospitalized patients. Subsequently, a report was published showing that in 397 hospitalized patients with moderate to severe disease, there was no difference in outcome comparing patients who received a 5 day course of remdesivir versus a 10 day course (20). There was no placebo arm. The analysis was complicated by an imbalance in clinical severity; the patients randomized to 10 days of treatment had significantly more severe disease than those in the 5 day group. The 14 day mortality in the 5 day group was 8% versus 11% in the 10 day group. A different study of remdesivir in hospitalized patients with moderate COVID-19 clinical status showed improved clinical status by day 11 compared to standard of care for a 5 day course of remdesivir, but not for a 10 day course (21). Mortality at 28 days was 1% for patients in the 5 day group, 2% for those in the 10 day group, and 2% for the standard of care group. A retrospective analysis of a cohort of 312 patients with severe disease treated with remdesivir showed a mortality of 7.6%% compared to 12.5% in a different historical retrospective cohort of 818 patients treated with standard of care (22). There has been no data provided on viral clearance for the U.S. remdesivir studies.

There were two randomized, active control clinical trials in China of favipiravir (FVP) (23,24). In a study of 35 patients receiving FVP, compared to 45 patients receiving LPV/R plus inhaled interferon

alpha, a shorter viral clearance time was found for the FVP arm (median (interquartile range, IQR), 4 (2.5–9) days versus 11 (8–13) days, $p < 0.001$) (23). The FVP arm also showed significant improvement in chest imaging compared with the control arm, with an improvement rate of 91.4% versus 62.2% ($p = 0.004$). In a larger Chinese trial comparing 116 patients on FVP to 120 on umifenovir, the 7 day clinical recovery rate was 55.9% for the umifenovir group and 71% in the FVP group (24). The Chinese Health Ministry, after reviewing the studies, concluded that FVP was efficacious against COVID-19. In Japan, a clinical registry containing 1918 hospitalized patients receiving FVP on a compassionate use basis was released on June 2, 2020 (25). There was no control group nor data on viral clearance. Patients were treated on average 3 days post admission to the hospital. The 30 day overall mortality was 11.6%. A press conference in July announced that an 89 patient controlled study in Japan was inconclusive due to failure to reach statistical significance in this small cohort. In Russia, a preliminary study of FVP showed reduced duration of viral shedding, and the drug was approved for clinical treatment beginning in multiple hospitals on June 12, 2020 (26). In India, Glenmark™ recently announced unpublished data on 150 patients confirming the favorable results of the Chinese studies, and FVP was released for treatment in that country.

Published studies on hydroxychloroquine (HCQ) have been controversial. A group in Marseille reported their experience with 3737 patients screened positive for SARS-Cov-2 immediately treated with HCQ and azithromycin (AZM), after excluding patients at risk of QT prolongation (27). Asymptomatic contacts with positive viral tests were included, so most of their subjects were outpatients seen in their day hospital in addition to those who did require hospitalization. They showed clearance of viral shedding in 89.4% of the patients by ten days. The overall mortality in their population was 0.9%,

none in patients under 60 years old, and no sudden cardiac deaths. They had no randomized control population.

There have been many retrospective large observational trials which suggest that hospitalized patients on HCQ have worse outcomes with possible cardiac dysrythmias (See TABLE 6) (31-35). The difficulty in analyzing retrospective observational data is in the possibility of selection bias choosing patients who were sicker for treatment. Conversely, in a large retrospective observational study at the Henry Ford Hospital System in Detroit, patients were selected for treatment based on an unpublished protocol, choosing sicker patients for HCQ treatment, and HCQ+AZM for those with most severe disease if there were no cardiac risk factors (36). Overall in-hospital mortality was 18.1% (95% CI:16.6%-19.7%); by treatment: HCQ+AZM, 157/783 (20.1% [95% CI: 17.3%-23.0%]), HCQ alone, 162/1202 (13.5% [95% CI: 11.6%-15.5%]), AZM alone, 33/147 (22.4% [95% CI: 16.0%-30.1%]), and neither drug, 108/409 (26.4% [95% CI: 22.2%-31.0%]).

In a randomized, controlled, Brazilian study, neither HCQ nor HCQ +AZM showed any clinical benefit in mild to moderate COVID-19 hospitalized patients (37). In the randomized RECOVERY trial, in 1542 hospitalized patients in the United Kingdom, there was no significant difference in the primary endpoint of 28-day mortality (26.8% hydroxychloroquine vs. 25% usual care; hazard ratio 1.09 [95% confidence interval 0.96-1.23]; $p$=0.18) (38).

In a retrospective comparison study at NYU Langone Health for all patients admitted between March 2 and April 5, 2020, there was a move to add zinc 100 mg daily to their standard HCQ plus AZM regimen (39). Zinc supplementation has shown benefit in viral diseases both in inhibiting viral replication, improvement of systemic immunity and reduction of duration of common cold symptoms There were 411 patients treated with HCQ+AZM+ zinc. There were only minor differences in the clinical characteristics of these patients compared to 521 patients on HCQ + AZM who did not receive zinc. There was a significantly lower mortality (13.1%) among the zinc treated patients compared to those who did not receive zinc (22.8%).

The prevailing current opinion on HCQ treatment of COVID-19 is based almost entirely on in-hospital data, with limited study in outpatients. In one large internet-based prevention study, with HCQ given for 5 days to healthy individuals with a significant exposure to SARS-Cov-2, the incidence of new illness compatible with COVID-19 did not differ significantly between participants receiving HCQ (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%]); absolute difference −2.4 percentage points (95% confidence interval, −7.0 to 2.2; $p$=0.35) (40). The same group also treated 423 patients with mild symptoms imputed to COVID-19 (41). At 14 days, 24% (49 of 201) of participants receiving HCQ had ongoing symptoms compared with 30% (59 of 194) receiving placebo ($p$ = 0.21).

A study in Spain of 293 patients with PCR-confirmed mild COVID-19, found no difference in viral load nor risk of hospitalization following 6 days HCQ treatment compared to untreated patients (42). The same group treated 1,116 healthy contacts of 672 Covid-19 index cases with HCQ while 1,198 were randomly allocated to usual care (43). There was no significant difference in the primary outcome of PCR-confirmed, symptomatic Covid-19 disease (6.2% usual care vs. 5.7% HCQ; risk ratio 0.89

[95% confidence interval 0.54-1.46]), nor evidence of prevention of SARS-CoV-2 transmission (17.8% usual care vs. 18.7% HCQ).

A large population study in Portugal surveyed all patients on chronic HCQ treatment and cross-verified against a mandatory database of patients registered with COVID-19 (44). The incidence of SARS-CoV-2 infection in patients receiving HCQ was 5.96%, compared to 7.45% in those not so treated. The adjusted odds ratio of a positive PCR test for HCQ chronic treatment was 0.51 (0.37-0.70).

Published results with Lopanovir/ritonavir (LPV/r) in hospitalized patients have been disappointing. In a randomized trial with 99 patients on LPV/r and 100 receiving standard care, there was no difference in time to clinical improvement, mortality or viral clearance (46). A press release, not yet published, from the RECOVERY trial stated no significant difference in the primary endpoint of 28-day mortality (22.1% LPV/r vs. 21.3% usual care; relative risk 1.04 [95% confidence interval 0.91-1.18];( $p$=0.58) in 1,596 hospitalized patients.

A possibly more favorable result was obtained in Hong Kong in a study of 86 patients assigned to triple combination therapy with LPV/r plus ribavirin plus interferon β-1 (47). Compared to a control group of 41 patients receiving LPV/r alone, the combination group had a significantly shorter median time from start of study treatment to negative SARS-Cov-2 nasopharyngeal swab (7 days [IQR 5–11]) than the control group (12 days [8–15]; hazard ratio 4.37 [95% CI 1.86–10.24], $p$=0·0010). The time to complete alleviation of symptoms was 4 days [IQR 3–8] in the combination group vs 8 days [7–9] in

the control group; HR 3.92 [95% CI 1.66–9.23. This study was interpreted not as supporting LPV/r therapy, but rather focusing on interferon β-1 as the primary treatment modality.

In Cuba, a combination of interferon-α-2b and interferon γ on background therapy of LPV/r and chloroquine, was successful in achieving viral clearance in 4 days in 78.6% of the patients compared to 40.6% of those receiving interferon-α-2b alone (50). A study of 81 hospitalized patients in Iran showed 28-day overall mortality significantly lower in an interferon β treated group than the control group (19% vs. 43.6% respectively, $p$= 0.015) (51). Early administration significantly reduced mortality (OR=13.5; 95% CI: 1.5-118). Interferon nasal drops were administered to 2944 medical staff people in Huabei province, with not a single case of COVID-19, but there was no randomized control group (52). Recently, a press release announced that a small British study of nebulized interferon β-1 had succeeded in reducing duration of hospitalization and mortality.

There have been many studies of immunomodulatory therapy to mitigate the hyperinflammatory phase of COVID-19 which have suggested reduction of mortality and need for intubation in hospitalized severe and critically ill patients (35, 54-64). Similar levels of improvement have now been reported for the IL-1 inhibitor anakinra (65-67). However, a press release by Roche Pharmaceuticals on the double blind COVACTA trial stated that there was no benefit of tocilizumab in clinical status, mortality (19.7% tocilizumab vs placebo = 19.4%), nor in ventilator free days.

Pre-COVID-19, glucocorticoid treatment had been a recognized treatment with mortality benefit for ICU patients in respiratory distress (68). In the RECOVERY trial, the dexamethasone arm studied 2104 patients randomly allocated to receive this agent for ten days compared to 4321 patients concurrently allocated to usual care (70). Overall, 454 (21.6%) patients allocated dexamethasone and 1065 (24.6%) patients allocated usual care died within 28 days (age adjusted rate ratio [RR] 0.83; 95% confidence interval [CI] 0.74 to 0.92; $p<0.001$). Dexamethasone reduced deaths by one-third in the subgroup of patients receiving invasive mechanical ventilation (29.0% vs. 40.7%, RR 0.65 [95% CI 0.51 to 0.82]; $p<0.001$) and by one-fifth in patients receiving oxygen without invasive mechanical ventilation (21.5% vs. 25.0%, RR 0.80 [95% CI 0.70 to 0.92]; $p=0.002$), but did not reduce mortality in patients not receiving respiratory support at randomization (17.0% vs.13.2%, RR 1.22 [95% CI 0.93 to 1.61]; $p=0.14$). Methylprednisolone has shown similar benefit in COVID-19 patients with acute respiratory failure (71-74), although a short 5 day course did not alter the very high mortality in a Brazilian study (75).

Colchicine, an anti-inflammatory agent, suggested benefit in the GRECCO, placebo-controlled, randomized clinical trial of 105 patients (76). The primary clinical end point of deterioration to mechanical ventilation or death was 14% in the control group (7 of 50 patients) and 1.8% in the colchicine group (1 of 55 patients) (odds ratio, 0.11; 95% CI, 0.01-0.96; p = 0.02).

There is also favorable data on convalescent plasma with a reduction in mortality (77-79). A meta-analysis including 4173 patient outcomes across a multinational series of studies concluded that convalescent plasma treatment yielded a 57% reduction in mortality (80). Based on evidence of safety in over

20,000 patients in an expanded access program coordinated by the Mayo Clinic, the U.S. FDA recently issued an emergency authorization for use of convalescent plasma (81).

Several vaccines have reported successful induction of antibody in early phase trials. Four vaccines have published data suggesting strong neutralizing antibody and cellular immunity response (84-87). An inactivated Chinese vaccine has recently reported strong neutralizing antibody effects (88). Very recently preliminary data from two Russian adenovector vaccines was released (89).

# DISCUSSION

SARS-Cov-2 overwhelmed medical preparedness for the pandemic. Current projections are for a continuation of new cases and deaths through the end of 2020 (90,91). Clinical trials to date have focused on hospitalized patients to try to prevent death. The modalities currently having emergency approval for treatment are solely directed at hospitalized patients. It is hoped that the use of remdesivir, convalescent plasma, anticoagulation and improved management of COVID-19 respiratory failure will lower the present rate of mortality which in some series has been as low as 6% but in most hospitals still approaches 20% (74). However, it is essential to prevent and to treat the initial viral infection so that hospitalization can be avoided. We face a dilemma in having no current prevention nor treatment for outpatients with mild to moderate disease, constituting 80% of the infected population and the primary mode of spread of SARS-Cov-2. The lessons learned in very sick hospitalized patients do not necessarily apply to the earlier viremic phase of the disease. Antiviral agents, such as remdesivir and favipiravir, and convalescent plasma are likely to be most effective during the early stage of viremia, which is prehospitalization.

Vaccines have been the sole hope held out by public health authorities to arrest SARS-Cov-2. Progress on vaccine development has been rapid, but the speed of development does not reduce the challenges of developing a vaccine to be administered to hundreds of millions of people. Certainly the 30 years of as yet unsuccessful efforts to produce an AIDS vaccine illustrate the worst case difficulties. Although neutralizing antibodies and memory T cells can be produced by the vaccine candidate, the demonstration of true protection requires observation and long-term follow-up of an exposed vaccinated population. No matter how rapidly a vaccine advances to Phase III testing, the duration of follow-up cannot be shortened, and for SARS-Cov-2 possibly prolonged due to several factors. First, there is a risk of immune enhancement of infection which occurs when induced antibodies increase entry and internalization of virus into myeloid cells (92). This major complication struck the newly developed dengue vaccine in 2017 (93). Second, the sinister autoimmune pathogenicity of SARS-Cov-2 raises the risk of delayed long-term harm if the virus is not fully and immediately eradicated by the initial immune response to the vaccine. Finally, the duration of protection is an open question. Studies of recurrent coronavirus infections suggest that infection may confer immunity for less than a year (94). For these reasons of needed long term safety observation, the deployment of an effective vaccine could be delayed.

Shortages of testing supplies in the United States have thus far limited the ability to positively diagnose the disease, resulting in the recommendation of home quarantine for the majority of patients with suspicious symptoms. Those shortages are being remedied. Now, there is a need for therapeutic interventions which can be used to treat outpatients with positive COVID-19 tests at the time of initial

symptoms, not waiting for deterioration requiring hospital care. The Marseille group demonstrated that it was possible to treat all outpatients with a positive COVID-19 test early in the viremic phase (27). They provided clinical and virologic data, but without a well-defined control group to justify their treatment with HCQ plus AZM. The NYU group treated all hospitalized patients with HCQ and AZM, and showed an impressive effect of addition of zinc sulfate, but they had no control group for HCQ plus AZM. Remdesivir administered intravenously for five days is not a practical daily outpatient treatment; Gilead© is attempting to develop an inhaled remdesivir formulation, but those efforts are only now beginning. Favipiravir, a tablet, could be used in early stages of infection and has now been released in Russia and in India, but not in the United States. It has known embryogenic risks, so its use requires restrictions on women of childbearing potential, as is the case with tretinoin for acne and thalidomide for multiple myeloma. Trials with camostat, the serine protease inhibitor, capable of blocking cell entry of SARS-Cov-2, are not due to end till the third or fourth quarter of the year. Similarly, a prevention trial with colchicine is not scheduled to end until the fourth quarter of 2020. The Solidarity Trial interferon arm is not scheduled to complete enrollment until 2021 and is a study of hospitalized patients. Convalescent plasma has been approved for emergency use in hospitalized patients. Potentially an infusion could be delivered to outpatients. Monoclonal antibodies based on the same principle are under study to prevent nursing home outbreaks, and could potentially be delivered to ambulatory patients. But, at this time, no outpatient therapy has been proven safe and effective in a phase III randomized, placebo-controlled study. There are strong arguments to avoid emergency use of agents until trials are completed and analyzed, but the agents suggested are not new. Most are drugs like the interferons, marketed and available for other conditions and with well-known safety profiles. There is a clear need for outpatient therapeutic intervention now.

There is a precedent to resolve the conflict between immediate clinical need and the requirements for rigorous controlled trials to prove efficacy. We should remember that the greatest success in fighting a pandemic occurred over the past two decades in the battle against the HIV virus which causes AIDS. AIDS was first recognized in 1981 in the MSM (men who have sex with men) community (95). The disease was considered a death sentence. There was widespread fear because there was no treatment, and projections of infection escalated into the millions. The first AIDS remedy was azidothymidine (AZT), synthesized in 1964 in the hope that it would combat cancer. Twenty years later Dr. Samuel Broder, head of the National Cancer Institute, showed that the drug had activity against the HIV virus in vitro (96). Burroughs Wellcome launched a rapidly conceived trial with just 300 patients. They stopped the trial in 16 weeks claiming that more patients survived on AZT. The FDA came under enormous pressure from AIDS activists to make the drug available, and it was approved on March 19, 1987, with only that one trial. It had taken 20 months for the FDA to give approval to release the drug. To this day, the design and results of the trial remain controversial.

The LGBT community continued to battle for early release of other medications to combat the AIDS pandemic. On October 11, 1988, a massive protest occurred at the FDA. It was back then Dr. Anthony Fauci who publicly advanced the idea of a parallel track to make drugs widely available even while studies are progressing: "*Clearly, the standard approach to the design of clinical trials—that is, rigid eligibility criteria as well as the strict regulatory aspects that attend clinical trial investigations and drug approval—was not well-suited to a novel, largely fatal disease such as this with no effective treat-*

*ments, and we had many intense discussions about how to make that approach more flexible and ethically sound. One example, which I and others worked closely with the AIDS activists to develop, was called a parallel track for clinical trials. The parallel track concept, which the United States Food and Drug Administration ultimately came to support, meant that there would be the standard type of highly controlled admission criteria and data collection for the clinical trial of a particular drug. In parallel, however, the drug also could be made available to those who did not meet the trial's strict admission criteria but were still in dire need of any potentially effective intervention, however unproven, for this deadly disease*" (97).

The parallel track advocated by Dr. Fauci was adopted. Today, there are 41 drugs or combinations approved by the FDA to treat and to prevent HIV infection. There is still no vaccine. There are now an estimated 1.1 million patients with HIV in the United States, most enjoying near normal life expectancy thanks to the antiviral agents. The CDC has contributed greatly to limit the spread of HIV by advocating safe sex practices, but social distancing is not the norm for HIV. Rather "treatment as prevention" for people with HIV using highly active antiretroviral regimens to prevent transmission as well as pre-exposure prophylaxis with a daily antiviral combination pill are currently endorsed by the CDC and adopted in wide segments of the at risk population (98).

In this pandemic crisis, we appeal to public health authorities to change the dynamic of current studies to outpatient care and to cross institutional, commercial and international boundaries to collate and combine all randomized controlled data submitted for all agents in Europe, China, Russia, Japan, India

and other countries, and by competing companies, whether officially published, posted on line, or unpublished to finalize confirmatory results. The Solidarity Trial is a model of what could and should be done to unify a worldwide effort to pursue randomized controlled studies in outpatients. At the same time, agents with favorable preliminary results and no safety issues should be made available through a parallel track. In Russia and India, the parallel track has been fully implemented, with FVP now offered as treatment throughout both countries, even as further confirmatory controlled trials proceed. Interferon β is one of the remaining randomized controlled Solidarity Trial options and is widely available in most countries. If vaccines can be brought forward now, it is reasonable to authorize their use at present in very large parallel track studies in at risk populations, such as healthcare workers and the elderly. China has begun vaccinating their military with one of their vaccines. Russia is proceeding to a voluntary vaccination program. The United Kingdom and the U.S. Centers for Disease Control are considering an emergency authorization program for vaccines before conclusion of the ongoing Phase 3 trials. However, it is unwise to rely solely on the hope for an eventual vaccination program to stop SARS-Cov2. Antiviral medication has succeeded in limiting HIV. Antiviral medication is just as important as annual vaccination for control of influenza. It is necessary for public health authorities to make hard decisions now despite limited current data and offer outpatient treatments on a broad front with no further delay.

## REFERENCES

1) WHO Coronavirus Disease (COVID-19) Dashboard

Data last updated: 2020/9/15, 3:57 PM

2) Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323(13): 1239-1242

3) Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091.

4) Connors JM, Levy JH. Thromboinflammation and the hypercoagulability of COVID-19. J Thromb Haemost. 2020 Apr 17 https://doi.org/10.1111/jth.14849.

5) Ricardo J, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation storm: Lancet Respir Med 2020; 8(6): e46-e47

6) https://www.nature.com/articles/d41586-020-01248-1

7) Park M, Ryan S, Thwaites RS, et al. COVID-19: Lessons from SARS and MERS Eur J Immun 2020; 50(3): 308-311

8) China National Health Commission. Chinese Clinical Guidance for COVID-19 Pneumonia Diagnosis and Treatment (7th edition 2020-03-16 12:00:32

9) Liu J, Cao R, Xu M,et al. Cell Discovery. 2020; 6:16 Cell Discovery https://doi.org/10.1038/s41421-020-0156-0www.nature.com/celldisc

10) Thorlund KT, Dron L, Park J et al. A real-time dashboard of clinical trials for COVID-19. Lancet Digital Health 2020;  2: e86-e87 published on line 24 Apr 20 https://doi.org/10.1016/ S2589-7500(20)30086-8

11)  Ngo BT, Rendell M. A systematic analysis of the time course to develop treatments for COVID-19medRxiv 2020.05.27.20115238; doi: https://doi.org/10.1101/2020.05.27.20115238

12) "'Solidarity' clinical trial for COVID-19 treatment". www.who.int. World Health Organization. Retrieved 22 April 2020

13) Haviernik J, Štefánik M, Fojtíková M et al. Arbidol (Umifenovir): A broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses. Viruses. 2018; 10(4): 184.

14) Uno Y. Camostat mesilate therapy for COVID-19. Intern Emerg Med. 2020 Apr 29 doi: 10.1007/s11739-020-02345-9

15) Brown BL, McCullough J. Treatment for emerging viruses: Convalescent plasma and COVID- Transfusion and Apheresis Science 2020;59: 102790

16) Chumakov K, Benn CS, Aaby P, et al. Can existing live vaccines prevent COVID-19? Science 2020; 368 (6496): 1187-1188

17) Wang Y, Zhang D, Guanhua Du G, et al. Remdesivir in adults with severe COVID-19: a randomised,double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395 (10236): 1569-1578

18) Grein J, Ohmagari N, Shin D. Compassionate use of remdesivir for patients with severe Covid-19N Engl J Med 2020; 328: 2327-2336

19) Beigel JH, Tomashek KM, Dodd LE. Remdesivir for the Treatment of Covid-19 — Preliminary Report. May 22, 2020. New Engl J Med. DOI: 10.1056/NEJMoa2007764

20) Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. New Engl J Med May 27, 2020 DOI: 10.1056/NEJMoa2015301

21) Spinner CD, Gottlieb RL, Criner GJ et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. A randomized clinical trial .JAMA. Published online August 21, 2020. doi:10.1001/jama.2020.16349

22) Olender SA, Perez KK, Go AS, et al . Remdesivir for severe COVID-19 versus a cohort receiving standard of care. Clinical Infectious Diseases, ciaa1041, https://doi.org/10.1093/cid/ ciaa1041 Published: 24 July 2020

23) Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: An open-label control study Engineering (Beijing). 2020;10.1016/j.eng.2020.03.007. doi:10.1016/j.eng.2020.03.007

24) Chen C, Huang J, Zhenshun Cheng Z, et al. Favipiravir versus Arbidol for COVID-19: A randomized clinical trial. medRxiv preprint doi: https://doi.org/10.1101/2020.03.17.20037432.this version posted March 20, 2020.

25) Preliminary Report of the Favipiravir Observational Study in Japan Favipiravir Observational Study Group. http://www.kansensho.or.jp/uploads/files/topics/ 2019ncov/ covid19_casereport_ en_200529.pdf Accessed 19 June 2020

26) Ivashchenko AA, Dmitriev KA, Vostokova NV, et al. AVIFAVIR for treatment of patients with moderate COVID-19: Interim results of a Phase II/III multicenter randomized clinical trial. Clinical Infectious Diseases, ciaa1176, https://doi.org/10.1093/cid/ciaa1176

27) Lagier JC, Million M, Gautret P, et al. Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Med Infect Dis. 2020 July-August; 36: 101791. . Available on line 25 June 2020

28) Chen Z, Hu J,Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv preprint doi:https://doi.org/10.1101/2020.03.22.20040758.this version posted March 30, 2020.

29) Chen J, Liu D, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) J Zhejiang Univ (Med Sci) 2020, Vol. 49 Issue (1): 0-0 DOI: 10.3785/j.issn.1008-9292.2020.03.03

30) Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients mainly with mild to moderate COVID-19: an open-label, randomized, controlled trial. BMJ 2020;369:m1849

31) Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. Med (2020), https://doi.org/10.1016/ j.medj.2020.06.001

32) Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. New Engl J Med 2020 ;382(25):2411-2418

33) Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 2020; 323(24): 2493-2502.

34) Mahévas M, Tran VT, Roumier M, et al. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020;369:m1844

35) Ip A, Berry DA, Hansen E, et al, Hydroxychloroquine and tocilizumab therapy in COVID-19 patients - An observational study. PLoS ONE 15(8): e0237693.

36) Arshad S, Kilgore P, Chaudhry ZS, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Inf Dis. 2020 ; 97: 396–403

37) Cavalcanti AB. Zampieri FG, Rosa RG, et al .Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. New Eng J Med published on line July 23, 2020 DOI: 10.1056/NEJMoa2019014

38) RECOVERY Collaborative Group. Effect of Hydroxychloroquine in hospitalized patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. medRxiv pre-print doi: https://doi.org/10.1101/2020.07.15.20151852

39) Carlucci P, Tania Ahuja T, Petrilli CM, et al. Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients medRxiv

doi: https://doi.org/10.1101/2020.05.02.20080036

40) Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med J 2020; 383:517-525

41) Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in nonhospitalized adults with early COVID-19.A randomized trial. Ann Int Med2020 Jul 16 : M20-4207

42) Mitjà O, Corbacho-Monné M, Ubals M, et al. Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial. Clinical Infectious Diseases, ciaa1009, https://doi.org/10.1093/cid/ciaa1009 Published: 16 July 2020

43) Mitjà O, Ubals M, Corbacho-Monné M, et al. A cluster-randomized trial of hydroxychloroquine as prevention of Covid-19 transmission and disease. medRxiv 2020.07.20.20157651; doi: https://doi.org/10.1101/2020.07.20.20157651

44) Ferreira A, Oliveira-e-Silva A ,Bettencourt P. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection. J Med Virol 2020:1-5J Med Virol. 2020;1–5 DOI: 10.1002/jmv.26286

45) Li Y, Xie Z, Lin W, et al. An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI.Med (N Y). 2020 May 19 doi: 10.1016/j.medj.2020.04.001

46) Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir–Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787-1799.

47) Hung IFN , Lung KC, Tso EYK et al Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, random-ised, phase 2 trial Lancet,2020 May 30;395(10238):1695-1704.

48) Estebanez M, Ramirez-Olivencia G, Mata T, et al. Clinical evaluation of IFN beta-1-b in COVID-19 pneumonia: a retrospective study. MedRxiv doi: https://doi.org /10.1101/ 2020.05.15.20084293

49) Pereda R, González D, Rivero HB, et al. Therapeutic effectiveness of interferon-alpha 2b against COVID-19: the Cuban experience. medRxiv preprint doi: https://doi.org/10.1101/2020.05.29.20109199.

50) PE Idelsis, Perez-Escribano J, Duncan-Robert Y, et al Effect and safety of combination of interferon alpha-2b and gamma or interferon alpha-2b for negativization of SARS-CoV-2 viral RNA medRxiv https://doi.org/10.1101/2020.07.29.20164251

51) Rahmani H, Davoudi-Monfared E,, Nourian A, et al. Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial. Int Immunopharmacol. 2020 Nov; 88: 106903. Published online 2020 Aug 24. doi: 10.1016/j.intimp.2020.106903

52) Meng Z, Wang T, Chen L, et al. An experimental trial of recombinant human interferon alpha nasal drops to prevent COVID-19 in medical staff in an epidemic area. medRxiv .https://doi.org/10.1101/ 2020.04.11.20061473

53) Bian H, Zheng ZH, Wei D. Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. medRxiv doi:https://doi.org/10.1101/ 2020.03.21.20040691

54) Xua X, Hanb M, Lia T, et al. Effective treatment of severe COVID-19 patients with tocilizumab 10970–10975 | Proc Natl Acad Sci | May 19, 2020 | vol. 117 | no. 20 www.pnas.org/cgi/doi/10.1073/pnas.2005615117

55) Somers EC, Eschenauer GA, Troost JP. Tocilizumab for treatment of mechanically ventilated patients with COVID-19. MedRxiv doi: https://doi.org/10.1101/2020.05.29.20117358

56) Rossi B, Nguyen LS, Zimmermann, et al. Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study medRxiv doi: https://doi.org/ 10.1101/2020.06.06.20122341

57) Martinez-Sanz J, Muriel A, l Ron R, et al. Effects of tocilizumab on mortality in hospitalized patients with COVID-19: A Multicenter Cohort Study. MedRxiv doi: https://doi.org/10.1101/2020.06.08.20125245

58) Petrak R, Skorodin N, Van Hise N, et al. Tocilizumab as a therapeutic agent for critically ill patients infected with SARS-CoV-2. MedRxiv doi: https://doi.org/10.1101/ 2020.06.05.20122622

59) Perrone P, Piccirillo MC, Ascierto PA, et al. Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 phase 2 trial. MedRXiv doi: https://doi.org/10.1101/2020.06.01.20119149

60) Garcia EM, Caballero VR, Albiach L,et al. Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection medRxiv doi: https://doi.org/ 10.1101/2020.06.05.20113738

61) Wadud N, Ahmed N, Shergil M, et al. Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration. MedRxiv doi: https://doi.org/10.1101/2020.05.13.20100081

62) Sanchez-Montalva A, Selares-Nadal J, Espinosa-Pereiro J, et al. Early outcomes of tocilizumab in adults hospitalized with severe COVID19. An initial report from the Vall dHebron COVID19 prospective cohort study.doi: https://doi.org/10.1101/2020.05.07.20094599

63) Ramaswamy M, Mannam P, Comer R, et al. Off-label real world experience using tocilizumab for patients hospitalized with COVID-19 disease in a regional community health system: A case-control study medRxiv. doi: https://doi.org/10.1101/2020.05.14.20099234

64) Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2020; 2(8): 2, e474-e484

65) Cavalli G, De Luca G, Campochiaro C, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol 2020; 2: e325–31

66) Cauchois R, Koubia M, Delarbreb D, et al. Early IL-1 receptor blockade in severe inflammatoryrespiratory failure complicating COVID-19. Proc Nat Acad Sci 2020; 117: 18951-18953

67) Huet T, Beaussier H, Voisin O, et al. Anakinra for severe forms of COVID-19: a cohort study. Lancet Rheumatol 2020; 2: e393-e400

68) Villar J, Ferrando C, Martínez D et al. Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267-276

69) Chroboczek T, Lacoste L, Wackenheim C, et al. Beneficial effect of corticosteroids in severe COVID-19 pneumonia: a propensity score matching analysis. MedRxiv: doi: https://doi.org/ 10.1101/2020.05.08.20094755

70) RECOVERY Collaborative Group. Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report. July 17, 2020 DOI: 10.1056/NEJMoa2021436

71) Salton F, Confalonieri P, Santus P, et al. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. medRxiv preprint doi: https://doi.org/10.1101/2020.06.17.20134031.this version posted June 25, 2020

72) Fadel R ,Morrison AR, Vahia A, et al. Early short-course corticosteroids in hospitalized patients with COVID-1. Clinical Infectious Diseases 2020; ciaa601, https://doi.org/10.1093/cid/ciaa601

73) Villar J, Confalonieri, M, Pastore, SM, et al. Rationale for prolonged corticosteroid treatment in the acute respiratory distress syndrome caused by Coronavirus Disease 2019. Crit Care Explor April 2020;2 :e0111

74) Marik PE, Kory P, Varon J, et al. MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale, Expert Review of Anti-infective Therapy https://doi.org/10.1080/14787210.2020.1808462 published on line 18 aug 2020

75) Jeronimo CMP, Farias MEL, BSc, Val FFA, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): A randomised, double-blind, phase iib, placebo-controlled trial Clinical Infectious Diseases, ciaa1177, https://doi.org/10.1093/cid/ciaa1177

76) Deftereos SG, Giannopoulos G, Dimitrios A, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with Coronavirus Disease 2019. The GRECCO-19 randomized clinical trial. JAMA Network Open. 2020;3:e2013136.

77) Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020 ;324(5):460-470.

78) Perotti C, Baldanti F, Bruno R, et al. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial. Haematologica. 2020 Jul 23;haematol.2020.261784. doi: 10.3324/haematol.2020.261784

79) Avendano-Sola C, Ramos-Martinez A,Munez-Rubio E, et al. Convalescent Plasma for COVID-19: A multicenter, randomized clinical trial. MedRxiv September 1, 2020. .https://doi.org/10.1101/2020.08.26.20182444doi:

80) Joyner MJ, Klassen SA, Senefeld JW, et al. ,Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy. MedRxiv posted August 28, 2020.https://doi.org/10.1101/2020.07.29.20162917doi: medRxiv pr

81) Joyner MJ, Bruno KA, Klassen SA, et al, Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients Mayo Clin Proc. 2020;95 (9):1888-1897

82) Freedberg DE, Conigliaro J, Sobieszczyk ME, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. Gastroenterology. 2020 May 22 doi: 10.1053/j.gastro.2020.05.053 [Epub ahead of print]

83) Rajter JC, Sherman M, Fatteh N, et al. ICON (Ivermectin in COvid Nineteen) study: Use of ivermectin is associated with lower mortality in hospitalized patients with COVID19. medRxiv doi: https://doi.org/10.1101/2020.06.06.20124461

84) Folegatti PM, J Ewer KJ, Parvinder K Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020 ;396(10249):467-478

85) Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA Vaccine against SARS-CoV-2 —preliminary report N Engl J Med. 2020 Jul 14;NEJMoa2022483.

doi: 10.1056/NEJMoa2022483

86) Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo controlled, phase 2 trial. Lancet 2020; 395(10240):, P1845-1854, June 13, 2020

87) Keech C, Albert G, Cho I, et al. Phase 1–2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine..New Engl J Med. DOI: 10.1056/NEJMoa2026920

88) Xia S, Duan K, Yuntao Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes. Interim analysis of 2 randomized clinical trials. JAMA 2020 ;e2015543.doi: 10.1001/jama.2020.15543

89) Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. Published online September 4, 2020 https://doi.org/10.1016/S0140-6736(20)31866-31

90) Liu M, Thomadsen R, Yao S. Forecasting the spread of COVID-19 under different reopening strategies. medRxiv preprint doi: https://doi.org/10.1101/2020.05.26.20113993

91) Institute for Health Metrics and Evaluation. COVID-9 projections . Covid 19.healthdata.org

92) Wan Y, Shang J, Sun S, et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J Virol 2020;94:e02015-19.

93) Fatima K, Syed NI. Dengvaxia controversy: impact on vaccine hesitancy. J Glob Health. 2018; 8(2): 020312.

94) Edridge AWD, Kaczorowska J, Hoste ACR et al. Coronavirus protective immunity is short-lasting.medRxiv preprint doi: https://doi.org/10.1101/2020.05.11.20086439.this version posted June 16, 2020.

95) Sepkowitz KA. AIDS-The first 20 years. N Engl J Med 2001; 344 (23):1764-1772

96) Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010; 85(1): 1-18

97) Fauci AS. Preface: Evolving ethical issues over the course of the AIDS pandemic. Public Health Rev 34, 2 (2012)

98) Harris NS, Johnson AS, Huang YA, et al. Vital Signs: Status of human immunodeficiency virus testing, viral suppression, and HIV pre-exposure prophylaxis - United States, 2013-2018. MMWR Morb Mortal Wkly Rep. 2019; 68 (11):1117-1123

TABLE 1. PUBLISHED STUDIES AS OF SEPTEMBER 15, 2020. Each agent is listed along with the country originating the publication. The type of control procedure: RCT: Randomized controlled study PLAC: Placebo , soc: standard of care which is variable depending on each location. AC: Active control: the control options are listed in parenthesis. OBS: retrospective observation study. lpv/r: lopanovir/ritonavir; hcq: hydroxychloroquine; azm: azithromycin; IFN: interferon. SEV: severe; CRIT: critical; MOD: moderate

| TREATMENT | LOCATION | TYPE OF CONTROL | NUMBER SUBJECTS | SETTING | SEVERITY | RESULTS |
|---|---|---|---|---|---|---|
| Remdesivir[17] | China | RCTPLAC vs soc | 273 | HOSP | SEV | mortality in remdesivir group 14%, control 13%<br>11% in remdesivir group with <10 days symptoms<br>Vs 14% in placebo group, no difference in viral clearance |
| Remdesivir[18] | U.S.A. | OBS. | 53 | HOSP | SEV,CRIT | Mortality 18% (6 of 34 patients on mechanical ventilation<br>5% 1 of 19 of those not receiving mechanical ventilation |
| Remdesivir[19] | U.S.A. | RCTPLAC | 1063 | HOSP | SEV,CRIT | 14 day mortality 7.6% vs 13.4% placebo |
| Remdesivir[20] | U.S.A. | AC(5 day vs 10 day, no control) | 397 | HOSP | MOD,SEV | 10 day group had more severe disease, mortality 8% in 5 day group 11% in 10 day group |
| Remdesivir[21] | U.S.A. | AC(5 day vs 10 day, vs soc) | 596 | HOSP | MOD | Improved clinical status in 5 day group but not in10 day group |
| Favipiravir (FVP)[23] | China | AC(lpv/r vs favipiravir) | 70 | HOSP | MOD,SEV | 4 day viral clearance time FPV vs 11 days lpv/r<br>CT scan improvement 92% fvp vs 62% lpv/r |

| | | | | | | |
|---|---|---|---|---|---|---|
| Favipiravir (FVP)[24] | China | AC (umifenovir vs favipiravir) | 240 | HOSP | MOD,SEV | Clinical recovery rate 56%umifenovir vs 71% fvp<br><br>time to fever reduction and cough shorter fvp |
| Favipiravir (FVP)[25] | Japan | OBS (no control) | 1918 | HOSP | MOD,SEV,CRIT | Mortality 11.6% at one month |
| Favipiravir (FVP)[26] | Russia | AC (vs soc) | 60 | HOSP | MOD | viral clearance achieved in 25/40 (62.5%) patients on fvp vs 6/20 (30.0%) patients on SOC (p=0.018) |
| HCQ[27] | France | OBS(hcq+azm, noncomparable control group) | 3737 | MIXED | MILD,MOD | 0.9% overall mortality, no sudden death, no cardiac arrythmias |
| HCQ[28] | China | RCT(soc) | 62 | HOSP | MOD | shorter time to temperature recovery<br><br>Pneumonia improvement 81% (HCQ) vs 55% soc<br><br>no progression to severe status any HCQ patient versus 4 of 17 (soc) |
| HCQ[29] | China | RCT(soc) | 30 | HOSP | MOD | no differences in viral clearance time |
| HCQ[30] | China | RCT(hcq vs soc) | 150 | HOSP | MILD,MOD | No difference in viral clearance at 28 days |
| HCQ[31] | U.S.A. | OBS(hcq vs no hcq) | 338 | HOSP | MOD,SEV | Mortality twice as high in patients chosen for HCQ treatment |
| HCQ[32] | U.S.A. | OBS (hcq vs no hcq) | 1376 | HOSP | MOD,SEV | no significant association between HCQ use and intubation or death<br><br>(hazard ratio, 1.04, 95% confidence interval, 0.82 to 1.32).<br><br>HCQ treated patients were sicker with ppO2 223 vs 360 for controls |

| | | | | | | |
|---|---|---|---|---|---|---|
| | | | | | | still lower than controls after propensity score matching 223 vs 273 |
| HCQ[33] | U.S.A. | OBS (hcq+azt vs hcq vs azt) | 1438 | HOSP | MOD,SEV | Overall in-hospital mortality was 20.3%,25.7% hcq+azt, 19.9% hcq alone<br><br>neither drug 17.7%, cardiac arrest more likely with hcq+azt |
| HCQ[34] | France | OBS (hcq vs no hcq) | 181 | HOSP | MOD,SEV | no difference in mortality or need to transfer to ICU |
| HCQ[35] | U.S.A. | OBS (hcq vs hcq plus azm, azm | 1914 | HOSP | MOD,SEV | 30-day unadjusted mortality for patients receiving hydroxychloroquine alone, azithromycin alone, the combination or neither drug was 25%, 20%, 18%, and 20%, |
| HCQ[36] | U.S.A. | OBS (hcq vs hcq plus azm, azm | 2541 | HOSP | MOD,SEV | Overall mortality was 18.1% (95% CI:16.6%-19.7%); by treatment: hcq+azt, (20.1% [95% CI: 17.3%-23.0%]), hcq alone, (13.5% [95% CI: 11.6%-15.5%]), azt alone,(22.4% [95% CI: 16.0%-30.1%]), neither drug, (26.4% [95% CI: 22.2%-31.0%]). |
| HCQ[37] | Brazil | RCT (hcq+azm, hcq, vs soc) | 504 | HOSP | MILD,MOD | No difference in clinical status of patients or mortality at 15 days |
| HCQ[38] | U.K. | RCT (hcq vs soc) | 1542 | HOSP | MOD,SEV | no significant difference in28-day mortality (26.8% hydroxychloroquine vs. 25% usual care; hazard ratio 1.09 [95% confidence interval 0.96-1.23]; p=0.18) ( |

| | | | | | | |
|---|---|---|---|---|---|---|
| HCQ[39] | U.S.A. | OBS (hcq+azt +zinc vs hzq +azt) | 932 | HOSP | MOD,SEV | Reduction in mortality with addition of zinc OR 0.449, 95% CI 0.271-0.744). |
| HCQ[40] | U.S.A. | RCTPLAC | 821 | OUTPAT | HEALTHY | No significant difference in incidence of subsequent COVID-19 infection (11.8% HCQ, 14.3% PLAC, p=0.35) |
| HCQ[41] | U.S.A. | RCTPLAC | 423 | OUTPAT | MILD | At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo (P = 0.21) |
| HCQ[42] | Spain | RCTPLAC | 293 | OUTPAT | MILD | no difference in viral load at 7 days after 6 days HCQ treatment nor risk of hospitalization compared to untreated patients |
| HCQ[43] | Spain | RCTPLAC | 2324 | OUTPAT | HEALTHY | no significant difference in the primary outcome of PCR-confirmed, symptomatic Covid-19 disease (6.2% usual care vs. 5.7% HCQ; risk ratio 0.89 [95% confidence interval 0.54-1.46]), nor evidence of prevention of SARS-CoV-2 transmission (17.8% usual care vs. 18.7% HCQ) |
| HCQ[44] | Portugal | OBS(HCQ vs no HCQ) | 1293 | OUTPATIENT | HEALTHY | odds ratio of SARS-CoV-2 infection for chronic treatment with HCQ 0.51 (0.37-0.70). |
| LPV/r[45] | China | AC(lpv/r vs umifenovir vs no antiviral) | 44 | HOSP | MOD,SEV | No differences in viral load, clinical status, or CT scan |
| LPV/r[46] | China | RCT(soc) | 199 | HOSP | SEV | No differences in mortality, viral load; time to clinical improvement 1 day less in lpv/r group |
| LPV/r[47] | Hong Kong | AC(lpv/r+ribavirin+beta interferon vs lpv/r+ribavirin) | 127 | HOSP | MOD.SEV | Triple combination of interferon beta-1b, lpv/r, and ribavirin yielded more rapid viral clearance but attributable primarily to interferon |

| | | | | | | |
|---|---|---|---|---|---|---|
| IFN- β-1a[48] | Spain | OBS | 256 | HOSP | MIXED | In hospital mortality of interferon treated patients 20.8% vs 27.3% in control group (p=0.23) |
| IFN- β-1a[49] | Cuba | OBS | 761 | HOSP | MIXED | Case fatality ratio 0.92 for interferon treated patients |
| IFN-α-2b[50] | Cuba | AC(RCT ( IFN- α-2b- vs IFN-α-2b + IFN- γ, background LPV/R +chloroquine) | 66 | HOSP | MIXED | Time to reach the elimination of Viral clearance 3 days for combined interferons vs 5 days for IFN- α-2b alone (p=0.0027 |
| IFN- β-1a[51] | Iran | RCT ( IFN- β-1a vs soc) | 81 | HOSP | SEV,CRIT | 28-day overall mortality significantly lower in the IFN then the control group (19% vs. 43.6% respectively, p= 0.015). Early administration significantly reduced mortality (OR=13.5; 95% CI: 1.5-118) |
| IFN-α nasal drops[52] | China | OBS | 2944 | OUTPAT | HEALTHY | No cases of COVID-19 compared to historical control |
| Meplazumab[53] | China | RCT(soc) | 38 | HOSP | MOD,SEV | Viral clearance 3 days (1.5-4.5) compared to 13 days(6.5-19.5) in control group |
| Tocilizumab[54] | China | OBS(no control) | 20 | HOSP | SEV,CRIT | no patient died, rapid defervescence, improvement in oxygenation |
| Tocilizumab[35] | U.S.A. | OBS (tocilizumab vs soc) | 1914 | HOSP | CRIT | 30 day unadjusted mortality with and without tocilizumab of 46% versus 56% |

| | | | | | | |
|---|---|---|---|---|---|---|
| Tocilizumab[55] | U.S.A. | OBS (tocilizumab vs soc) | 154 | HOSP | CRIT | tocilizumab was associated with a 45% reduction in hazard of death [hazard ratio 0.55 (95% CI 0.33, 0.90)] |
| Tocilizumab[56] | France | Matched cohort (tocilizumab vs soc) | 168 | HOSP | SEV | tocilizumab was associated with a 51% reduction in composite of death and mechanical ventilation(HR)=0.49 (95% confidence interval (95CI)=0.3-0.81), p-value=0.005) |
| Tocilizumab[57] | Spain | OBS | 1229 | HOSP | SEV | Tocilizumab associated with decreased risk of death (aHR 0.34, 95% CI 0.16 to 0.72, p=0.005) and ICU admission or death (aHR 0.38, 95% CI 0.19 to 0.81, p=0.011) among patients with baseline CRP >150 mg/L, |
| Tocilizumab[58] | U.S.A. | OBS (tocilizumab early vs late treatment)) | 154 | HOSP | CRIT | increased survival and avoidance mechanical ventilation with early treatment |
| Tocilizumab[59] | Italy | OBS | 1221 | HOSP | SEV | 15.6% moratility at 14 days, 20% at 30 days in tocilizumab treated patients |
| Tocilizumab[60] | Spain | OBS( tocilizumab vs soc) | 171 | HOSP | MOD,SEV | Tocilizumab associated with decreased risk OF ICU admission (10.3% vs. 27.6%, P= 0.005) and need of invasive ventilation (0 vs 13.8%, P=0.001) |
| Tocilizumab[61] | U.S.A. | OBS (tocilizumab vs soc) | 94 | HOSP | CRIT | Survival rate 48 % in the control group and 61% in patients who received Tocilizumab P < 0.00001. |

| | | | | | | |
|---|---|---|---|---|---|---|
| Tocilizumab[62] | Spain | OBS( tocilizumab vs soc) | 82 | HOSP | CRIT | 7 day mortality with tocilizumab 26.8%. Age adjusted HR 2.1 if tocilizumab begun after onset of respiratory failure |
| Tocilizumab[63] | U.S.A. | OBS (tocilizumab vs soc) | 86 | HOSP | SEV | Reduced risk of death in patients who received Tocilizumab (RR 0.472; 95% CI 0.449-0.497 P < 0.00001) |
| Tocilizumab[64] | Italy | OBS(tocilizumab vs soc) | 544 | HOSP | SEV | tocilizumab treatment was associated with a reduced risk of invasive mechanical ventilation or death (adjusted hazard ratio 0·61, 95% CI 0·40–0·92; p=0·020). |
| Anakinra[65] | Italy | OBS(vs soc) | 45 | HOSP | SEV | At 21 days, survival 90% in the high-dose anakinra group vs 56% in soc group (p=0·009). Mechanical ventilation-free survival 72% in the anakinra group vs 50% in soc group (p=0·15). |
| Anakinra[66] | France | OBS(vs soc) | 22 | HOSP | SEV | 12 anakinra treated patients showed greater clinical improvement and decreased cytokine levels compared to control group with |
| Anakinra[67] | France | OBS(vs soc) | 96 | HOSP | SEV | Admission to the ICU for invasive mechanical ventilation or death occurred in 13 (25%) patients in the anakinra group and 32 (73%) patients in the historical group (hazard ratio [HR] 0·22 [95% CI 0·11–0·41; p<0·0001). |
| Corticosteroid[69] | France | OBS(vs no steroid) | 70 | HOSP | MOD,SEV | Reduced risk of intubation -47.1% (95% confidence interval -71.8% to -22.5%). |
| Dexamethasone[70] | U.K. | RCT(soc) | 6119 | HOSP | MOD,SEV | Dexamethasone reduced 28-day mortality by 35% in patients receiving invasive mechanical ventilation (rate ratio 0.65 [95% CI 0.51 to 0.82]; p<0.001) and by 20% in patients receiving oxygen without invasive mechanical ventilation (rate ratio 0.80 [95% CI 0.70 to 0.92]; p=0.002 |

| | | | | | | |
|---|---|---|---|---|---|---|
| Methylprednisolone[82] | Italy | RCT(soc) | 173 | HOSP | SEV | Mehtylprednisoloong group had fewer deaths (6 vs. 21, adjusted HR=0.29; 95% CI: 0.12-0.73) and more days off invasive MV (24.0 plus-or-minus sign 9.0 vs. 17.5 plus-or-minus sign 12.8; p=0.001) |
| Methylprednisolone[71] | U.S.A. | OBS(soc) | 213 | HOSP | SEV | Early short course of methylprednisolone resulted in decrease need for ICU care, mechanical ventilation and mortality ((34.9% vs 54.3%, P = .005) |
| Methylprednisolone[75] | Brazil | RCT(soc) | 393 | HOSP | MOD,SEV | Overall 28-day mortality was 76/199 (38.2%) in the placebo group vs 72/194 (37.1%) in group which received methylprednisolone short 5 day curse (P=0.629) |
| Colchicine[76] | Greece | RCT(colchicine vs soc) | 105 | HOSP | MOD,SEV | The clinical primary end point rate was 14.0% in the control group (7 of 50 patients) and 1.8%in the colchicine group (1 of 55 patients) (odds ratio, 0.11; 95%CI, 0.01-0.96; P = .02). |
| Convalescent plasma[77] | China | RCT( soc) | 103 | HOSP | SEV.CRIT | time to clinical improvement at 28 days was 4.9 days shorter (95% CI, −9.33 to −0.54 days) in convalescent plasma group (HR, 2.15 [95% CI, 1.07-4.32]; P = .03). No significant difference in critically ill patients. Mortality 28-day mortality (15.7% convalescent plasma vs 24.0% control ; P = .30) |
| Convalescent plasma[78] | Italy | OBS | 46 | HOSP | CRIT | 7 day mortality 6.5% |
| Convalescent plasma[79] | Spain | RCT(soc) | 81 | HOSP | MOD,SEV | Mortality 0% for conv plasma group vs 9.3% for control at 29 |

| | | | | | | |
|---|---|---|---|---|---|---|
| Famotidine[82] | U.S.A. | OBS(famotidine vs soc) | 1620 | HOSP | MOD,SEV | HR for famotidine for death or intubation 0.43, 95% CI ( 0.21-0.88 ) |
| Ivermectin[83] | U.S.A. | OBS(ivermectin vs soc) | 280 | HOSP | MOD,SEV | lower mortality in the ivermectin group (25.2% versus 15.0%, OR 0.52, 95% CI 0.29-0.96, P=.03) |
| ChAdOx1-nCoV19[84] | U.K. | RCT (plac) | 1077 | OUTPAT | HEALTHY | 100% spike protein neutralising antibody, spike specific T cell responses |
| mRNA1273[85] | U.S.A. | RCT(plac) | 45 | OUTPAT | HEALTHY | High neutralising antibody titiers, positive Th1-CD4 response |
| Ad5 vectored Covid Vaccine[86] | China | RCT(plac) | 603 | OUTPAT | HEALTHY | Significant neutralizing antibody titers and positive T cell response |
| NVX-Cov2373[87] | Australia | RCT(plac) | 134 | OUTPAT | HEALTHY | Significant neutralizing antibody titers and positive T cell response |
| Coronavac[88] | China | RCT(plac) | 330 | OUTPAT | HEALTHY | Significant neutralizing antibody titers and positive T cell response |
| Ad5 and Ad26 vectored Covid Vaccines[89] | Russia | OBS | 76 | OUTPAT | HEALTHY | Significant neutralizing antibody titers and positive T cell response |

(a)




(b)




Figure 1: THE PHASES OF COVID-19 INFECTION. Asymptomatic viremia typically lasts for 5 days followed by symptoms of an upper respiratory infection. The immune response takes hold over the next week. Pneumonic infiltrates begin to appear. In patients destined for severe infection, a hyperinflammatory reaction takes hold, leading to worsening of pulmonary symptoms, hypoxia, and potentially acute respiratory distress syndrome.

SUPPLEMENTARY TABLE 1: ALL TRIALS REVIEWED. All interventions reviewed are listed with the registration number in the listing database, the country of origin, the severity of illness, the clinical setting whether hospital or outpatient, they type of intervention, the number of patients projected, and the category of the intervention. CGRP: Calcitonin gene related peptide CHIMED: Traditional Chinese medication; IFN: Interferons ;LPV: Lopanovir/ritanovir; RAS: Renin angiotensin system

| CLINICAL TRIAL REGISTRATION | COUNTRY | SEVERITY | SETTING | INTERVENTION | NO SUBJECTS | CLASS OF AGENT |
|---|---|---|---|---|---|---|
| NCT04355962 | Switzerland | NA | ICU | Sevoflurane | 64 | ANESTHESIA |
| NCT04348370 | United States | Non-severe | Healthcare Workers | BCG Vaccine | 1800 | ANGIOGENESIS INHIBITOR |
| NCT04305106 | China | Severe | Hospital | Bevacizumab | 140 | ANGIOGENESIS INHIBITOR |
| NCT04275414 | China | Severe | Hospital | Bevacizumab | 20 | ANGIOGENESIS INHIBITOR |
| IR/46977 | Iran | NA | Outpatient | Minocycline | 40 | ANTIBIOTIC |
| NCT04369365 | Austria | NA | Outpatient | AZT | 200 | ANTIBIOTIC |
| EU/2020-001640-26/GB/ | United Kingdom | NA | ICU | Actilyse | 24 | ANTICOAG |
| NCT04365309 | China | NA | Unclear | Aspirin | 128 | ANTICOAG |
| NCT04348383 | Spain | Severe | Hospital | Defibrotide | 120 | ANTICOAG |
| NCT04359277 | United States | NA | Hospital | Enoxaparin | 1000 | ANTICOAG |
| NCT04345848 | Switzerland | NA | Hospital, ICU | Enoxaparin | 200 | ANTICOAG |
| CHI51265 | China | NA | Hospital | LMW Heparin | 120 | ANTICOAG |
| NCT04368377 | Italy | NA | ICU | Tirofiban, Clopidogrel, Acetylsalicylic acid, Fondaparinux | 5 | ANTICOAG |
| CHI50474 | China | Unspecified | Unclear | Celecoxib | 60 | ANTIINFLAMMATORY |
| NCT04308317 | China | Mixed | Unclear | Tetrandrine | 60 | ANTIINFLAMMATORY |
| CHI49738 | China | Mixed | Outpatient, Hospital | Tranilast | 60 | ANTIINFLAMMATORY |
| NCT04339426 | United States | NA | Unclear | Atovaquorine, AZT | 25 | ANTIMALARIAL |
| IR/47099 | Iran | NA | Hospital | Chloroquine + Azithromycin + Melatonin | 82 | ANTIMALARIAL |
| NCT04333914 | France | NA | Hospital | Chloroquine analog, nivolumab, TCZ | 273 | ANTIMALARIAL |
| NCT04321278 | Brazil | Severe | Hospital | Azithromycin , HCQ | 440 | ANTIMALARIAL |
| NCT04324463 | Canada | NA | Outpatient, Hospital | Azithromycin , HCQ | 1500 | ANTIMALARIAL |
| NCT04322396 | Denmark | NA | Hospital | Azithromycin , HCQ | 226 | ANTIMALARIAL |
| EU/2020-001469-35/PL/ | Poland | NA | Outpatient | Chlorine phosphate (Arechin) | 400 | ANTIMALARIAL |
| NCT04347980 | France | Severe | Hospital | Dexamethasone, HCQ | 122 | ANTIMALARIAL |
| NCT04351191 | Pakistan | Non-severe | Outpatient | HCQ | 400 | ANTIMALARIAL |
| NCT04351516 | Germany | Mixed | Outpatient | HCQ | 350 | ANTIMALARIAL |
| NCT04346667 | Pakistan | NA | Outpatient | HCQ | 400 | ANTIMALARIAL |
| NCT04362332 | Netherlands | NA | Hospital | HCQ | 950 | ANTIMALARIAL |

| | | | | | | |
|---|---|---|---|---|---|---|
| NCT04353037 | United States | NA | Healthcare Workers, Outpatient | HCQ | 850 | ANTIMALARIAL |
| NCT04354870 | United States | NA | Healthcare Workers | HCQ | 350 | ANTIMALARIAL |
| NCT04349371 | United States | Non-severe | Healthcare Workers | HCQ | 350 | ANTIMALARIAL |
| IR/47090 | Iran | NA | Healthy Exposed | HCQ | 1000 | ANTIMALARIAL |
| CHI49420 | China | NA | Unclear | HCQ | 300 | ANTIMALARIAL |
| NCT04341441 | United States | NA | Healthcare Workers | HCQ | 3000 | ANTIMALARIAL |
| NCT04308668 | United States | Mixed | Healthy Exposed, Healthcare Workers, Outpatient | HCQ | 3000 | ANTIMALARIAL |
| NCT04329923 | United States | Mixed | Healthcare Workers, Outpatient, Hospital | HCQ | 400 | ANTIMALARIAL |
| NCT04333654 | United States | Non-severe | Outpatient | HCQ | 210 | ANTIMALARIAL |
| NCT04329611 | Canada | NA | Outpatient | HCQ | 1660 | ANTIMALARIAL |
| NCT04328493 | Vietnam | NA | Hospital | HCQ | 250 | ANTIMALARIAL |
| NCT04328961 | United States | None | Healthy Exposed | HCQ | 2000 | ANTIMALARIAL |
| NCT04342169 | United States | Non-severe | Outpatient | HCQ | 400 | ANTIMALARIAL |
| NCT04323527 | Brazil | NA | Hospital | HCQ | 440 | ANTIMALARIAL |
| NCT04345692 | United States | NA | Hospital | HCQ | 350 | ANTIMALARIAL |
| NCT04342650 | Brazil | NA | Unclear | HCQ | 210 | ANTIMALARIAL |
| NCT04333225 | United States | None | Healthcare Workers | HCQ | 360 | ANTIMALARIAL |
| NCT04342221 | Germany | NA | Hospital | HCQ | 220 | ANTIMALARIAL |
| NCT04328467 | United States | NA | Healthcare Workers | HCQ | 3500 | ANTIMALARIAL |
| NCT04334382 | United States | Non-severe | Outpatient | HCQ | 1550 | ANTIMALARIAL |
| NCT04331834 | Spain | None | Healthcare Workers | HCQ | 440 | ANTIMALARIAL |
| CHI49524 | China | Mixed | Unclear | HCQ | 360 | ANTIMALARIAL |
| CHI49482 | China | Severe | Hospital | HCQ | 100 | ANTIMALARIAL |
| CHI49536 | China | Non-severe | Outpatient | HCQ | 100 | ANTIMALARIAL |
| CHI49607 | China | NA | Unclear | HCQ | 100 | ANTIMALARIAL |
| CHI48880 | China | NA | Unclear | HCQ | 300 | ANTIMALARIAL |
| EU/2020-001270-29/DK/ | Denmark | Mixed | Hospital | HCQ | 350 | ANTIMALARIAL |
| NCT04318444 | United States | None | Healthy Exposed | HCQ | 1600 | ANTIMALARIAL |
| NCT04315896 | Mexico | Severe | Hospital | HCQ | 500 | ANTIMALARIAL |
| NCT04318015 | Mexico | None | Healthcare Workers | HCQ | 400 | ANTIMALARIAL |
| NCT04316377 | Norway | Mixed | Hospital | HCQ | 202 | ANTIMALARIAL |
| ISRCTNISRCTN86534580 | United Kingdom | NA | Outpatient | HCQ | 3000 | ANTIMALARIAL |
| IR/46932 | Iran | NA | Healthy Exposed, Healthcare Workers | HCQ | 500 | ANTIMALARIAL |
| NCT04369742 | United States | NA | Hospital | HCQ | 626 | ANTIMALARIAL |
| NCT04363450 | United States | NA | Healthcare Workers | HCQ | 1700 | ANTIMALARIAL |
| NCT04332991 | United States | Severe | Hospital | HCQ | 510 | ANTIMALARIAL |

| | | | | | | |
|---|---|---|---|---|---|---|
| NCT04334967 | United States | Non-severe | Outpatient | HCQ | 1250 | ANTIMALARIAL |
| NCT04351620 | United States | Non-severe | Outpatient | HCQ | 20 | ANTIMALARIAL |
| NCT04345653 | United States | Non-severe | Healthcare Workers | HCQ | 45 | ANTIMALARIAL |
| CHI50843 | China | NA | Hospital | HCQ | 80 | ANTIMALARIAL |
| CHI49317 | China | NA | Unclear | HCQ | 78 | ANTIMALARIAL |
| CHI49218 | China | Severe | Hospital | HCQ | 80 | ANTIMALARIAL |
| CHI49612 | China | NA | Unclear | HCQ | 100 | ANTIMALARIAL |
| CHI48968 | China | NA | Hospital | HCQ | 20 | ANTIMALARIAL |
| NCT04261517 | China | NA | Unclear | HCQ | 30 | ANTIMALARIAL |
| IR/46946 | Iran | NA | Healthy Unexposed | HCQ | 60 | ANTIMALARIAL |
| NCT04322123 | Brazil | NA | Hospital, ICU | HCQ , Azithromycin | 630 | ANTIMALARIAL |
| IR/46536 | Iran | NA | Hospital | HCQ , LPV/R , Oseltamivir | 50 | ANTIMALARIAL |
| JPJRCTS031190227 | Japan | NA | Hospital | HCQ , LPV/R , Oseltamivir | 50 | ANTIMALARIAL |
| IR/47200 | Iran | Moderate | Hospital | HCQ, Arbidol | 40 | ANTIMALARIAL |
| NCT04336332 | United States | Non-severe | Outpatient, Hospital | HCQ, azithromycin | 160 | ANTIMALARIAL |
| NCT04335552 | United States | Mixed | Hospital | HCQ, azithromycin | 500 | ANTIMALARIAL |
| NCT04344379 | France | Non-severe | Healthcare Workers | HCQ, azithromycin | 900 | ANTIMALARIAL |
| NCT04329832 | United States | NA | Hospital | HCQ, Azithromycin | 300 | ANTIMALARIAL |
| NCT04345861 | France | NA | Hospital | HCQ, AZT | 150 | ANTIMALARIAL |
| NCT04354428 | United States | NA | Outpatient | HCQ, AZT | 630 | ANTIMALARIAL |
| NCT04344444 | United States | NA | Hospital | HCQ, Azt | 600 | ANTIMALARIAL |
| NCT04341727 | United States | NA | Hospital | HCQ, AZT | 500 | ANTIMALARIAL |
| EU/2020-001527-14/NL/ | Netherlands | NA | Hospital | HCQ, AZT | 60 | ANTIMALARIAL |
| IR/46968 | Iran | NA | Hospital | HCQ, AZT, Naproxen, LPV/r, Corticosteroids | 906 | ANTIMALARIAL |
| NCT04341870 | France | NA | Hospital | HCQ, AZT, Sarilumab | 60 | ANTIMALARIAL |
| NCT04370262 | United States | NA | Hospital | HCQ, Famotidine | 1170 | ANTIMALARIAL |
| NCT04344457 | United States | Non-severe | Outpatient | HCQ, Indomethacin, azithromycin | 80 | ANTIMALARIAL |
| NCT04344457 | United States | Non-severe | Outpatient | HCQ, Indomethacin, azithromycin | 80 | ANTIMALARIAL |
| NCT04343092 | Iraq | Mixed | Hospital | HCQ, Ivermectin | 50 | ANTIMALARIAL |
| IR/46926 | Iran | NA | Outpatient | HCQ, LPV/r | 60 | ANTIMALARIAL |
| IR/47022 | Iran | NA | Hospital | HCQ, LPV/r | 100 | ANTIMALARIAL |
| NCT04328285 | France | NA | Healthcare Workers | HCQ, LPV/r, | 1200 | ANTIMALARIAL |
| IR/46561 | Iran | Severe | Hospital | HCQ, LPV/r, | 20 | ANTIMALARIAL |
| IR/46814 | Iran | NA | Hospital | HCQ, LPv/r, Atazanavir/r, Teicoplanin | 40 | ANTIMALARIAL |
| NCT04343768 | Iran | Mixed | Hospital | HCQ, LPV/r, IFN | 60 | ANTIMALARIAL |
| IR/46790 | Iran | NA | Hospital | HCQ, LPV/r, Sofosbuvir-Velpatasvir | 80 | ANTIMALARIAL |

| | | | | | | |
|---|---|---|---|---|---|---|
| IR/47119 | Iran | NA | Hospital | HCQ, Thalidomide | 60 | ANTIMALARIAL |
| NCT04325893 | France | NA | Unclear | HCQ/placebo | 1300 | ANTIMALARIAL |
| ISRCTNISRCTN14326006 | Canada | NA | Healthcare Workers | Hydroxychloroquine | 988 | ANTIMALARIAL |
| IR/46940 | Iran | NA | Unclear | LPV/r, HCQ, Herbal medicine | 40 | ANTIMALARIAL |
| NCT04328012 | United States | NA | Hospital | LPV/r, HCQ, losartan | 4000 | ANTIMALARIAL |
| ISRCTNISRCTN50189673 | United Kingdom | Mixed | Hospital | LPV/r, IFN, HCQ, steroids | 5000 | ANTIMALARIAL |
| NCT04332094 | Spain | Non-severe | Hospital | HCQ , TCZ, azithromycin | 276 | ANTIMALARIAL PLUS IMMUNE MODULATOR |
| IR/46887 | Iran | Mixed | Unclear | Levamisole | 50 | ANTIPARASITIC |
| NCT04348409 | Brazil | Mixed | Hospital | Nitazoxanide | 50 | ANTIPARASITIC |
| NCT04341493 | Mexico | NA | Unclear | Nitazoxanide | 86 | ANTIPARASITIC |
| IR/46576 | Iran | NA | Outpatient, Hospital | Noscapine | 125 | ANTITUSSIVE |
| NCT04330638 | Belgium | Severe | Hospital, ICU | Anakinra, siltuximab, TCZ | 342 | ANTIVIRAL |
| NCT04339712 | Greece | Severe | Unclear | Anakinra, TCZ | 40 | ANTIVIRAL |
| NCT04324489 | China | Severe | Hospital | Antiviral | 4 | ANTIVIRAL |
| IR/47087 | Iran | NA | Hospital | Arbidol | 200 | ANTIVIRAL |
| CHI49165 | China | Non-severe | Outpatient | Arbidol | 380 | ANTIVIRAL |
| CHI49532 | China | NA | Hospital | Azvudine | 20 | ANTIVIRAL |
| CHI50507 | China | Mixed | Unclear | Azvudine | 10 | ANTIVIRAL |
| NCT04358614 | Italy | NA | Hospital | Baricitinib | 12 | ANTIVIRAL |
| NCT04321096 | Denmark | NA | Hospital | Camostat | 580 | ANTIVIRAL |
| IR/46573 | Iran | Mixed | Hospital | Camostat | 40 | ANTIVIRAL |
| NCT04276688 | China | NA | Hospital | Combination Antiviral | 127 | ANTIVIRAL |
| NCT04291729 | China | NA | Hospital | Combination Antiviral | 11 | ANTIVIRAL |
| NCT04255017 | China | NA | Unclear | Combination Antiviral | 400 | ANTIVIRAL |
| CHI50136 | China | NA | Unclear | Combination Antiviral | 30 | ANTIVIRAL |
| NCT04261270 | China | Mixed | Hospital | Combination Antiviral | 60 | ANTIVIRAL |
| CHI49918 | China | Mixed | Hospital | Danoprevir , Ritonavir | 60 | ANTIVIRAL |
| NCT04345276 | China | NA | Hospital | Danoprevir, Ritonavir | 40 | ANTIVIRAL |
| NCT04252274 | China | NA | Unclear | Darunavir And Cobicistat | 30 | ANTIVIRAL |
| NCT04304053 | Spain | Non-severe | Outpatient | Darunavir/Cobicistat , HCQ | 3040 | ANTIVIRAL |
| CHI49790 | China | Mixed | Unclear | Ebastine | 100 | ANTIVIRAL |
| NCT04334928 | Spain | Non-severe | Healthcare Workers | Emtricitabine/tenofovir, HCQ | 4000 | ANTIVIRAL |
| NCT04333589 | China | NA | Unclear | Favipiravir | 210 | ANTIVIRAL |
| NCT04358549 | United States | NA | Hospital | Favipiravir | 50 | ANTIVIRAL |
| CHI49988 | China | NA | Unclear | Favipiravir | 30 | ANTIVIRAL |
| CHI49510 | China | NA | Hospital | Favipiravir | 60 | ANTIVIRAL |

| | | | | | | |
|---|---|---|---|---|---|---|
| JPJRCTS031190226 | Japan | NA | Hospital | Favipiravir | 50 | ANTIVIRAL |
| JPjRCTs041190120 | Japan | NA | Outpatient | Favipiravir | 86 | ANTIVIRAL |
| NCT04310228 | China | NA | Unclear | Favipiravir , TCZ | 150 | ANTIVIRAL |
| CHI50137 | China | NA | Hospital | Favipiravir Vs. Arbidol | 240 | ANTIVIRAL |
| IR/46942 | Iran | NA | Hospital | Favipiravir, LPV/r | 84 | ANTIVIRAL |
| CHI51126 | China | NA | Hospital | Favipiravir, TCZ | 150 | ANTIVIRAL |
| CHI49042 | China | NA | Outpatient | Favirapir, LPV/r | 90 | ANTIVIRAL |
| JapicCTI-205238 | Japan | Mixed | Hospital | FVP | 96 | ANTIVIRAL |
| NCT04319900 | China | NA | Unclear | FVP, HCQ | 150 | ANTIVIRAL |
| CHI51329 | China | NA | Resolved Discharged | HCQ , /- Favipiravir | 150 | ANTIVIRAL |
| IR/46897 | Iran | NA | Hospital | HCQ, Arbidol, LPV/r | 100 | ANTIVIRAL |
| IR/47078 | Iran | NA | Hospital | HCQ, Atazanavir/r, Vitamin C | 110 | ANTIVIRAL |
| NCT04355052 | Israel | NA | Hospital | HCQ, AZT, Camostat mesilate | 250 | ANTIVIRAL |
| IR/46783 | Iran | NA | Hospital | HCQ, Favipiravir, LPV/r | 324 | ANTIVIRAL |
| CHI51141 | China | Non-severe | Outpatient | Interferon, ribavirin, arbidol, ribavirin | 30 | ANTIVIRAL |
| registroclinico.sld.cu/en/trials/RPCEC00000307 | Cuba | Mixee | Hospital | Interferon α, Interferon λ | 134 | ANTIVIRAL |
| IR/47012 | Iran | Unclear | Unclear | Ivermecin | 100 | ANTIVIRAL |
| CHI50251 | China | Mixed | Unclear | Ixekizumab , Antiviral | 40 | ANTIVIRAL |
| CHI51112 | China | NA | Unclear | Lopinavir/ritonvair | 90 | ANTIVIRAL |
| CHI48782 | China | Mixed | Outpatient | LPV/r , Interferon | 108 | ANTIVIRAL |
| NCT04252885 | China | NA | Unclear | LPV/r, Arbidol | 125 | ANTIVIRAL |
| NCT04275245 | China | NA | Unclear | Mepaluzumab | 20 | ANTIVIRAL |
| NCT04280705 | United States | Severe | Hospital | Remdesivir | 800 | ANTIVIRAL |
| NCT04292899 | United States | Severe | Hospital | Remdesivir | 6000 | ANTIVIRAL |
| NCT04292730 | United States | Mixed | Hospital | Remdesivir | 1600 | ANTIVIRAL |
| EU/2020-001052-18/ES/ | Denmark | NA | Hospital | Remdesivir | 440 | ANTIVIRAL |
| NCT04321616 | Norway | Severe | Hospital, ICU | Remdesivir, HCQ | 700 | ANTIVIRAL |
| IR/46463 | Iran | Mixed | Hospital | Sofosbuvir | 70 | ANTIVIRAL |
| IR/46784 | Iran | NA | Hospital | Sofosbuvir | 60 | ANTIVIRAL |
| IR/46885 | Iran | NA | Hospital | Sofosbuvir + ribavirin | 48 | ANTIVIRAL |
| IR/46567 | Iran | NA | Hospital | Sofosbuvir/Lepdiasvir, HCQ , Oseltamivir, LPV/r | 50 | ANTIVIRAL |
| EU/2020-001244-26/AT/ | Austria | NA | ICU | Solnatide | 40 | ANTIVIRAL |
| CHI49723 | China | NA | Hospital | Triazavirin | 240 | ANTIVIRAL |
| NCT04321993 | Canada | Mixed | Hospital | LPV/r, HCQ, Baricitinib, Sarilumab | 1000 | ANTIVIRAL + IMMUNE MODULATOR |
| NCT04347031 | Russia | NA | Hospital | Melfoquine, HCQ, AZT, TCZ | 320 | ANTIVIRAL + IMMUNE MODULATOR |
| NCT04351763 | Poland | Mixed | Hospital | Amiodarone, Verapamil | 804 | CARDIOVASCULAR |

| | | | | | | |
|---|---|---|---|---|---|---|
| NCT04304313 | China | Mixed | Unclear | Sildenafil | 10 | CARDIOVASCULAR |
| NCT04319731 | United States | NA | Hospital | Amniotic Fluid | 10 | CELL THERAPY |
| CHI51404 | China | NA | Unclear | Cell Product | 20 | CELL THERAPY |
| NCT04324996 | China | NA | Unclear | Engineered Cells | 90 | CELL THERAPY |
| IR/47264 | Iran | NA | Hospital | Natural Killer Cells | 70 | CELL THERAPY |
| NCT04280224 | China | NA | Unclear | Natural-Killer Cells | 30 | CELL THERAPY |
| NCT04361942 | Spain | NA | ICU | Stem Cell | 24 | CELL THERAPY |
| NCT04339660 | China | NA | Unclear | Stem Cell | 30 | CELL THERAPY |
| IR/47156 | Iran | Mild/moderate | Unclear | Stem Cell Therapy | 20 | CELL THERAPY |
| NCT04349631 | United States | Non-severe | Healthcare Workers | Stem Cells | 56 | CELL THERAPY |
| NCT04355728 | United States | NA | Hospital, ICU | Stem Cells | 24 | CELL THERAPY |
| IR/47110 | Iran | NA | ICU | Stem Cells | 10 | CELL THERAPY |
| NCT04333368 | France | Severe | ICU | Stem Cells | 60 | CELL THERAPY |
| NCT04336254 | China | Severe | Hospital | Stem Cells | 20 | CELL THERAPY |
| NCT04331613 | China | Severe | ICU | Stem Cells | 9 | CELL THERAPY |
| CHI51904 | China | Severe | Unclear | Stem Cells | 36 | CELL THERAPY |
| CHI51050 | China | Severe | Hospital | Stem Cells | 20 | CELL THERAPY |
| CHI49812 | China | NA | Unclear | Stem Cells | 20 | CELL THERAPY |
| CHI49901 | China | Severe | Hospital | Stem Cells | 16 | CELL THERAPY |
| CHI41760 | China | Severe | Hospital | Stem Cells | 30 | CELL THERAPY |
| CHI49146 | China | Severe | Hospital | Stem Cells | 63 | CELL THERAPY |
| NCT04252118 | China | NA | Unclear | Stem Cells | 20 | CELL THERAPY |
| NCT04288102 | China | Severe | Hospital | Stem Cells | 90 | CELL THERAPY |
| NCT04313322 | Jordan | NA | Unclear | Stem Cells | 5 | CELL THERAPY |
| NCT04269525 | China | Severe | ICU | Stem Cells | 10 | CELL THERAPY |
| IR/46789 | Iran | NA | Hospital | Stem Cells | 5 | CELL THERAPY |
| IR/47030 | Iran | NA | Hospital, ICU | Stem Cells | 6 | CELL THERAPY |
| CHI49674 | China | Mixed | Hospital | Stem Cells | 120 | CELL THERAPY |
| NCT04348435 | United States | Non-severe | Healthcare Workers | Stem Cells | 100 | CELL THERAPY |
| CHI49254 | China | Mixed | Hospital | Stem Cells | 200 | CELL THERAPY |
| NCT04367077 | United States | NA | Hospital | Stem Cells | 400 | CELL THERAPY |
| NCT04346615 | United States | Mixed | Hospital | Vazegepant | 120 | CGRP |
| NCT04333550 | Iran | Mixed | Hospital, Unclear | Deferoxamine | 50 | CHELATING AGENT |
| CHI49631 | China | Non-severe | Unclear | TCM Exercise | 160 | CHIMED |
| CHI51030 | China | NA | Resolved Discharged | TCM Exercise | 28 | CHIMED |
| CHI49762 | China | Non-severe | Unclear | TCM Injectable | 348 | CHIMED |

| | | | | | | |
|---|---|---|---|---|---|---|
| CHI49222 | China | NA | Unclear | TCM Injectable | 238 | CHIMED |
| CHI49220 | China | Non-severe | Outpatient | TCM Injectable | 160 | CHIMED |
| CHI50115 | China | Non-severe | Unclear | TCM Injectable | 80 | CHIMED |
| CHI50306 | China | Severe | Hospital | TCM Injectable | 60 | CHIMED |
| CHI49748 | China | NA | Hospital | TCM Injectable | 50 | CHIMED |
| CHI49104 | China | NA | Outpatient | TCM Injectable | 60 | CHIMED |
| CHI50586 | China | Mixed | Unclear | TCM Injectable | 60 | CHIMED |
| CHI49297 | China | Mixed | Outpatient, Hospital | TCM Injectable | 90 | CHIMED |
| CHI50025 | China | Severe | Unclear | Traditional Chinese Medicine | 120 | CHIMED |
| CHI52699 | China | NA | Unclear | Traditional Chinese Medicine | 200 | CHIMED |
| CHI52477 | China | NA | Unclear | Traditional Chinese Medicine | 300 | CHIMED |
| CHI52414 | China | NA | Healthy Exposed | Traditional Chinese Medicine | 2000 | CHIMED |
| NCT04334265 | China | Unspecified | Unclear | Traditional Chinese Medicine | 750 | CHIMED |
| CHI52106 | China | NA | Unclear | Traditional Chinese Medicine | 300 | CHIMED |
| CHI51100 | China | NA | Outpatient, Hospital | Traditional Chinese Medicine | 2840 | CHIMED |
| CHI51240 | China | NA | Resolved Discharged | Traditional Chinese Medicine | 144 | CHIMED |
| CHI50202 | China | NA | Unclear | Traditional Chinese Medicine | 204 | CHIMED |
| CHI49647 | China | NA | Unclear | Traditional Chinese Medicine | 132 | CHIMED |
| CHI49543 | China | Non-severe | Outpatient | Traditional Chinese Medicine | 180 | CHIMED |
| CHI49348 | China | Mixed | Resolved Discharged | Traditional Chinese Medicine | 100 | CHIMED |
| CHI49408 | China | NA | Hospital | Traditional Chinese Medicine | 408 | CHIMED |
| CHI49453 | China | NA | Unclear | Traditional Chinese Medicine | 120 | CHIMED |
| CHI49287 | China | NA | Unclear | Traditional Chinese Medicine | 200 | CHIMED |
| CHI49380 | China | Severe | Hospital | Traditional Chinese Medicine | 160 | CHIMED |
| CHI48792 | China | NA | Unclear | Traditional Chinese Medicine | 200 | CHIMED |
| CHI48985 | China | NA | Healthy Exposed | Traditional Chinese Medicine | 600 | CHIMED |
| CHI48988 | China | NA | Outpatient | Traditional Chinese Medicine | 400 | CHIMED |
| CHI49080 | China | NA | Unclear | Traditional Chinese Medicine | 1000 | CHIMED |
| CHI51139 | China | NA | Unclear | Traditional Chinese Medicine | 400 | CHIMED |
| CHI49051 | China | NA | Unclear | Traditional Chinese Medicine | 400 | CHIMED |
| CHI48860 | China | Mixed | Outpatient, Hospital | Traditional Chinese Medicine | 140 | CHIMED |
| CHI48824 | China | NA | Unclear | Traditional Chinese Medicine | 60 | CHIMED |
| CHI50082 | China | Mixed | Hospital | Traditional Chinese Medicine | 96 | CHIMED |
| CHI50462 | China | NA | Resolved Discharged | Traditional Chinese Medicine | 20 | CHIMED |
| CHI51028 | China | Non-severe | Unclear | Traditional Chinese Medicine | 24 | CHIMED |
| CHI50793 | China | NA | Resolved Discharged | Traditional Chinese Medicine | 120 | CHIMED |

| | | | | | | |
|---|---|---|---|---|---|---|
| CHI49014 | China | NA | Unclear | Traditional Chinese Medicine | 400 | CHIMED |
| CHI49852 | China | Severe | Unclear | Traditional Chinese Medicine | 60 | CHIMED |
| CHI49387 | China | NA | Unclear | Traditional Chinese Medicine | 30 | CHIMED |
| CHI49490 | China | Severe | Unclear | Traditional Chinese Medicine | 80 | CHIMED |
| CHI48886 | China | Severe | Hospital | Traditional Chinese Medicine | 42 | CHIMED |
| IR/46775 | Iran | NA | Hospital | Traditional medicine | 80 | CHIMED |
| IR/46782 | Iran | NA | Hospital | Traditional medicine | 68 | CHIMED |
| NCT04251871 | China | NA | Unclear | Traditional Medicine Oral | 150 | CHIMED |
| CHI48898 | China | NA | Unclear | Traditional Medicine Oral | 240 | CHIMED |
| CHI48889 | China | Non-severe | Unclear | Traditional Medicine Oral | 240 | CHIMED |
| CHI50476 | China | NA | Resolved Discharged | Traditional Medicine Oral | 100 | CHIMED |
| CHI50986 | China | Non-severe | Unclear | Traditional Medicine Oral | 100 | CHIMED |
| CHI51018 | China | Non-severe | Outpatient | Traditional Medicine Oral | 128 | CHIMED |
| CHI48773 | China | None | Healthy Unexposed | Traditional Medicine Oral | 20000 | CHIMED |
| CHI44213 | China | Mixed | Hospital | Traditional Medicine Oral | 100 | CHIMED |
| CHI49301 | China | Mixed | Hospital | Traditional Medicine Oral | 120 | CHIMED |
| CHI49138 | China | Mixed | Hospital | Traditional Medicine Oral | 160 | CHIMED |
| CHI49402 | China | Mixed | Outpatient, Hospital | Traditional Medicine Oral | 300 | CHIMED |
| CHI49502 | China | NA | Hospital | Traditional Medicine Oral | 110 | CHIMED |
| CHI49422 | China | NA | Unclear | Traditional Medicine Oral | 600 | CHIMED |
| CHI48861 | China | NA | Unclear | Traditional Medicine Oral | 100 | CHIMED |
| IR/46678 | Iran | Unspecified | Hospital | Traditional Medicine Oral | 374 | CHIMED |
| IR/46721 | Iran | Unspecified | Outpatient | Traditional Medicine Oral | 100 | CHIMED |
| CHI50126 | China | NA | Hospital | Traditional Medicine Oral | 300 | CHIMED |
| CHI48775 | China | NA | Unclear | Traditional Medicine Oral | 300 | CHIMED |
| NCT04279197 | China | NA | Unclear | Traditional Medicine Oral | 136 | CHIMED |
| CHI52958 | China | Unclear | Unclear | Traditional medicine oral | 120 | CHIMED |
| CHI52942 | China | Unclear | Unclear | Traditional medicine oral | 200 | CHIMED |
| CHI49435 | China | Mixed | Unclear | Traditional Medicine Oral | 40 | CHIMED |
| NCT04347382 | Pakistan | NA | Hospital | Traditional Medicine Oral | 30 | CHIMED |
| CHI49666 | China | Mixed | Unclear | Traditional Medicine Oral | 72 | CHIMED |
| CHI50662 | China | NA | Unclear | Traditional Medicine Oral | 50 | CHIMED |
| CHI49753 | China | Mixed | Hospital | Traditional Medicine Oral | 20 | CHIMED |
| CHI49425 | China | Mixed | Hospital | Traditional Medicine Oral | 72 | CHIMED |
| CHI49131 | China | NA | Hospital | Traditional Medicine Oral | 60 | CHIMED |
| IR/46637 | Iran | Unspecified | Hospital | Traditional Medicine Oral | 60 | CHIMED |

| | | | | | | |
|---|---|---|---|---|---|---|
| IR/46715 | Iran | Unspecified | Hospital | Traditional Medicine Oral | 60 | CHIMED |
| IR/47019 | Iran | Unclear | Unclear | Traditional medicine oral | 80 | CHIMED |
| CHI50059 | China | Severe | Hospital | Plasma Product | 100 | CONV PLASMA |
| NCT04355897 | United States | NA | Hospital | Convalescent plasma | 100 | CONV PLASMA |
| NCT04362176 | United States | NA | Hospital | Convalescent plasma | 500 | CONV PLASMA |
| NCT04359810 | United States | NA | Hospital | Convalescent plasma | 105 | CONV PLASMA |
| NCT04357106 | Mexico | NA | ICU | Convalescent plasma | 10 | CONV PLASMA |
| NCT04347681 | Saudi Arabia | NA | Hospital, ICU | Convalescent plasma | 40 | CONV PLASMA |
| IR/46973 | Iran | NA | Hospital | Convalescent plasma | 60 | CONV PLASMA |
| IR/47115 | Iran | NA | Hospital | Convalescent plasma | 30 | CONV PLASMA |
| IR/47266 | Iran | NA | ICU | Convalescent plasma | 10 | CONV PLASMA |
| CHI50537 | China | Mixed | Hospital | Convalescent plasma | 50 | CONV PLASMA |
| IR/46931 | Iran | NA | Hospital | Convalescent plasma | 12 | CONV PLASMA |
| IR/47212 | Iran | NA | Hospital | Immunoglobulin | 15 | CONV PLASMA |
| IR/46811 | Iran | NA | Hospital | Immunoglobulin | 50 | CONV PLASMA |
| IR/47014 | Iran | NA | Hospital | Immunoglobulin, HCQ, LPV/r, Ribavirin | 100 | CONV PLASMA |
| NCT04342182 | Netherlands | Severe | Hospital | Plasma | 426 | CONV PLASMA |
| NCT04344535 | United States | Mixed | Hospital | Plasma | 500 | CONV PLASMA |
| NCT04345523 | Spain | NA | Hospital | Plasma | 278 | CONV PLASMA |
| IR/46759 | Iran | Severe | Hospital | Plasma | 200 | CONV PLASMA |
| NCT04364737 | United States | NA | Hospital | Plasma | 300 | CONV PLASMA |
| NCT04346446 | India | Severe | Hospital | Plasma | 20 | CONV PLASMA |
| NCT04343755 | United States | Severe | Hospital | Plasma | 55 | CONV PLASMA |
| NCT04327349 | Iran | NA | Unclear | Plasma | 30 | CONV PLASMA |
| IR/47058 | Iran | NA | ICU | Plasma | 32 | CONV PLASMA |
| IR/47163 | Iran | Severe | Hospital, ICU | Plasma | 357 | CONV PLASMA |
| CHI49081 | China | Severe | Hospital | Plasma Product | 200 | CONV PLASMA |
| NCT04343261 | United States | NA | Hospital | Plasma Product | 15 | CONV PLASMA |
| NCT04340050 | United States | NA | Hospital | Plasma Product | 10 | CONV PLASMA |
| CHI51072 | China | Severe | ICU | Plasma Product | 10 | CONV PLASMA |
| CHI50727 | China | Severe | Hospital | Plasma Product | 30 | CONV PLASMA |
| CHI49544 | China | Mixed | Outpatient, Hospital | Plasma Product | 90 | CONV PLASMA |
| CHI49861 | China | Mixed | Hospital | Plasma Product | 10 | CONV PLASMA |
| CHI49533 | China | NA | ICU | Plasma Product | 20 | CONV PLASMA |
| NCT04321421 | Italy | Severe | ICU | Plasma Product | 49 | CONV PLASMA |
| IR/47169 | Iran | NA | Unclear | Purified protein derivative | 50 | DIAGNOSTIC |

| | | | | | | |
|---|---|---|---|---|---|---|
| CHI49664 | China | NA | Unclear | Electrotherapy | 40 | ELECTROTHERAPY |
| IR/47015 | Iran | NA | ICU | Hemodialysis | 10 | HEMODIALYSIS |
| IR/47234 | Iran | NA | Outpatient | Echinacea + Ginger | 100 | HERBAL |
| NCT04322344 | Italy | NA | Hospital | Escin | 120 | HERBAL |
| IR/47018 | Iran | NA | Hospital | Foot bath | 60 | HYGIENE |
| NCT04344236 | United States | NA | Unclear | Nasal rinses | 48 | HYGIENE |
| NCT04254874 | China | Mixed | Unclear | Combination Antiviral | 100 | IFN |
| NCT04350281 | China | Severe | Hospital, ICU | IFN, HCQ | 80 | IFN |
| NCT04350671 | Iran | Severe | Hospital | IFN, HCQ, LPV/r, | 40 | IFN |
| CHI50470 | China | NA | Unclear | Interferon Therapy | 328 | IFN |
| EU/2020-001023-14/GB/ | United Kingdom | NA | Hospital | Interferon Therapy | 400 | IFN |
| NCT04331899 | United States | Non-severe | Outpatient | Interferon Therapy | 120 | IFN |
| NCT04320238 | China | None | Healthcare Workers | Interferon Therapy | 2944 | IFN |
| CHI49224 | China | Mixed | Unclear | Interferon Therapy | 100 | IFN |
| IR/46665 | Iran | Unspecified | Hospital | Interferon Therapy | 40 | IFN |
| NCT04365153 | United States | NA | Hospital | Canakinumab | 45 | IMMUNE MODULALTOR |
| CHI50934 | China | NA | ICU | Blood purification | 20 | IMMUNE MODULATOR |
| NCT04347226 | United States | NA | Hospital | BMS-986253 | 138 | IMMUNE MODULATOR |
| NCT04371367 | France | NA | ICU | Avdoralimab | 108 | IMMUNE MODULATOR |
| EU/2020-001736-95/GB/ | United Kingdom | Mixed | Unclear | Bemcentinib | 825 | IMMUNE MODULATOR |
| NCT04317040 | United States | Severe | Hospital | Cd24f | 230 | IMMUNE MODULATOR |
| NCT04343989 | United States | NA | ICU | Clazakizumab | 90 | IMMUNE MODULATOR |
| NCT04345614 | United States | Severe | Hospital | CM4620 | 120 | IMMUNE MODULATOR |
| NCT04328480 | Argentina | Severe | Hospital | Colchicine | 2500 | IMMUNE MODULATOR |
| NCT04322682 | United States | NA | Outpatient | Colchicine | 6000 | IMMUNE MODULATOR |
| NCT04360980 | Iran | NA | Hospital | Colchicine | 80 | IMMUNE MODULATOR |
| NCT04363437 | United States | NA | Hospital | Colchicine | 70 | IMMUNE MODULATOR |
| CHI48809 | China | NA | Hospital | Cyotkine protein injection | 90 | IMMUNE MODULATOR |
| NCT04361526 | Spain | NA | ICU | Cytokine Adsorption | 40 | IMMUNE MODULATOR |
| CHI49065 | China | NA | Outpatient, Hospital | Cytokine Protein Injection | 480 | IMMUNE MODULATOR |
| NCT04344080 | Germany | NA | ICU | Cytosorb | 24 | IMMUNE MODULATOR |
| NCT04346797 | France | NA | Hospital, ICU | Eculizumab | 120 | IMMUNE MODULATOR |
| NCT04324021 | Italy | Mixed | Healthcare Workers, Unclear | Emapalumab, Anakinra | 54 | IMMUNE MODULATOR |
| IR/46837 | Iran | Severe | Hospital, ICU | Extracorporeal Blood Purification | 10 | IMMUNE MODULATOR |
| CHI49632 | China | NA | ICU | Extracorporeal Blood Purification | 60 | IMMUNE MODULATOR |
| IR/46786 | Iran | Unspecified | Hospital | Fingolimod | 40 | IMMUNE MODULATOR |

| | | | | | | |
|---|---|---|---|---|---|---|
| NCT04280588 | China | Mixed | Hospital | Fingolimod | 30 | IMMUNE MODULATOR |
| NCT04333420 | Netherlands | Severe | Hospital | IFX-1 | 130 | IMMUNE MODULATOR |
| CHI50017 | China | Severe | Hospital | Jakotinib Hydrochloride | 16 | IMMUNE MODULATOR |
| NCT04351152 | United States | Mixed | Hospital | Lenziulumab | 238 | IMMUNE MODULATOR |
| NCT04343651 | United States | NA | Unclear | Leronimab | 75 | IMMUNE MODULATOR |
| NCT04343651 | United States | NA | Unclear | Leronimab | 75 | IMMUNE MODULATOR |
| NCT04343651 | United States | NA | Unclear | Leronimab | 75 | IMMUNE MODULATOR |
| NCT04347239 | United States | NA | Hospital | Leronlimab | 390 | IMMUNE MODULATOR |
| NCT04342897 | United States | NA | Hospital | LY3127804 | 200 | IMMUNE MODULATOR |
| CHI48907 | China | NA | Unclear | M1 Macrophage Suppressor | 45 | IMMUNE MODULATOR |
| NCT04334044 | Mexico | NA | Unclear | Ruxolitinib | 20 | IMMUNE MODULATOR |
| NCT04338958 | Germany | Severe | Hospital | Ruxolitinib | 200 | IMMUNE MODULATOR |
| NCT04326920 | Belgium | Severe | Hospital | Sargramostim | 80 | IMMUNE MODULATOR |
| EU/2020-001162-12/FR/ | Canada | Severe | Hospital | Sarilumab | 460 | IMMUNE MODULATOR |
| NCT04327388 | Canada | Severe | Hospital | Sarilumab | 300 | IMMUNE MODULATOR |
| NCT04315298 | United States | Severe | Hospital | Sarilumab | 400 | IMMUNE MODULATOR |
| NCT04359901 | United States | NA | Hospital | Sarilumab | 120 | IMMUNE MODULATOR |
| NCT04357808 | Spain | NA | Hospital | Sarilumab | 30 | IMMUNE MODULATOR |
| NCT04349098 | United States | Severe | Hospital | Selinexor | 230 | IMMUNE MODULATOR |
| NCT04329650 | Spain | Mixed | Hospital | Siltuximab | 200 | IMMUNE MODULATOR |
| NCT04348695 | Spain | Mixed | Hospital | Simvastatin, ruxolitinib | 94 | IMMUNE MODULATOR |
| NCT04341675 | United States | Mixed | Hospital | Sirolimus | 30 | IMMUNE MODULATOR |
| NCT04371640 | United States | NA | Hospital | Sirolimus | 40 | IMMUNE MODULATOR |
| NCT04322773 | Denmark | Severe | Hospital | TCZ | 200 | IMMUNE MODULATOR |
| GERDRKS00021238 | Germany | NA | ICU | TCZ | 200 | IMMUNE MODULATOR |
| NCT04335071 | Switzerland | Severe | Hospital | TCZ | 100 | IMMUNE MODULATOR |
| CHI49409 | China | Mixed | Hospital | TCZ | 188 | IMMUNE MODULATOR |
| NCT04320615 | United States | Severe | Hospital | TCZ | 330 | IMMUNE MODULATOR |
| NCT04317092 | Italy | Severe | Hospital | TCZ | 400 | IMMUNE MODULATOR |
| NCT04361552 | United States | NA | Hospital | TCZ | 180 | IMMUNE MODULATOR |
| NCT04363853 | Mexico | Severe | Hospital, ICU | TCZ | 200 | IMMUNE MODULATOR |
| NCT04331795 | United States | NA | Hospital | TCZ | 50 | IMMUNE MODULATOR |
| NCT04346355 | Italy | Mixed | Hospital | TCZ | 398 | IMMUNE MODULATOR |
| IR/47021 | Iran | NA | ICU | TCZ | 10 | IMMUNE MODULATOR |
| NL8504 | Netherlands | NA | Hospital | TCZ | 354 | IMMUNE MODULATOR |
| EU/2020-001770-30/BE/ | Belgium | Severe | Hospital | TCZ | 60 | IMMUNE MODULATOR |

| | | | | | | |
|---|---|---|---|---|---|---|
| CHI50693 | China | Severe | Hospital | TCZ , Adalimumab | 60 | IMMUNE MODULATOR |
| NCT04335305 | Spain | Severe | Hospital | TCZ, pembrolizumab | 24 | IMMUNE MODULATOR |
| CHI49161 | China | Severe | Hospital | Thymosin | 120 | IMMUNE MODULATOR |
| NCT04341116 | United States | Severe | Hospital | TJ003234 | 144 | IMMUNE MODULATOR |
| CHI49215 | China | NA | Hospital | vMIP | 40 | IMMUNE MODULATOR |
| NCT04350580 | France | Severe | ICU | Immunoglobulin | 138 | IVIG |
| IR/47219 | Iran | Severe | Hospital, ICU | IVIG, LPV/r | 20 | IVIG |
| CHI49075 | China | Mixed | Hospital | Asc09/Ritonavir | 160 | LPV |
| CHI49514 | China | Mixed | Outpatient, Hospital, ICU | Carriomycin | 520 | LPV |
| CHI49263 | China | NA | Outpatient | HCQ, LPV/r | 112 | LPV |
| NCT04364022 | Switzerland | NA | Healthy Exposed | HCQ, LPV/r | 420 | LPV |
| CHI48684 | China | NA | Hospital | LPV/r | 160 | LPV |
| CHI48991 | China | NA | Outpatient | LPV/r | 328 | LPV |
| NCT04330690 | Canada | Mixed | Hospital | LPV/r | 440 | LPV |
| NCT04321174 | Canada | None | Healthy Exposed | LPV/r | 1220 | LPV |
| NCT04307693 | South Korea | Non-severe | Outpatient | LPV/r | 150 | LPV |
| CHI50057 | China | NA | Unclear | LPV/r | 60 | LPV |
| NCT04365127 | United States | NA | Hospital | Progesterone | 40 | MATABOLIC |
| NCT04365699 | United States | NA | Hospital | AT-001 | 500 | METABOLIC |
| IR/46639 | Iran | NA | Hospital | Atorvastatin | 100 | METABOLIC |
| NCT04350593 | United States | Mixed | Hospital | Dapagliflozin | 900 | METABOLIC |
| NCT04359329 | United States | NA | Outpatient | Estradiol | 110 | METABOLIC |
| IR/46762 | Iran | NA | Outpatient | Medium-chain triglyceride | 120 | METABOLIC |
| IR/46690 | Iran | Mixed | Hospital | Metformin | 200 | METABOLIC |
| IR/47334 | Iran | NA | Hospital | Sitagliptin | 84 | METABOLIC |
| IR/47141 | Iran | Unclear | Outpatient | Lithium | 40 | MINERAL |
| IR/47244 | Iran | Unclear | Hospital | Azithromycin + Oseltamivir + LPV/r + Atazanavir + Hydroxychloroquine | 110 | MULTITHERAPY |
| IR/46538 | Iran | NA | Hospital | HCQ , Oseltamivir , LPV/r , IFN | 30 | MULTITHERAPY |
| NCT04366089 | Italy | NA | Hospital | HCQ, Azithromycin, Oxygen, Probiotic, Dietary supplement | 152 | MULTITHERAPY |
| IR/46810 | Iran | NA | Hospital | HCQ, Corticosteroids, Interferon, Immunoglobulin | 105 | MULTITHERAPY |
| IR/46853 | Iran | NA | Hospital | HCQ, Sof+Dac, Lithium, Trifluoprazine + trihexyphenidyl | 80 | MULTITHERAPY |
| NCT04331470 | Iran | NA | Unclear | Levamisole, LPV/r, HCQ | 30 | MULTITHERAPY |
| NCT04350684 | Iran | Mixed | Hospital | IFN, HCQ, LPV/R, Umifenovir | 40 | MULTITHERAPY |
| IR/46681 | Iran | Mixed | Hospital | TCZ, LPV/r, HCQ, oseltamivir | 40 | MULTITHERAPY |
| IR/47052 | Iran | Unclear | Unclear | LPV/r, Naproxen, HCQ, Oseltamivir | 101 | MULTITHERAPY |
| IR/46533 | Iran | NA | Unclear | Pirfenidone, Chloroquine, LPV/r, Oseltamivir | 40 | MULTITHERAPY |

| | | | | | | |
|---|---|---|---|---|---|---|
| NCT04366245 | Spain | NA | Hospital | Plasma, HCQ, LPV/r, Azithromycin | 72 | MULTITHERAPY |
| NCT04315948 | France | Severe | Hospital | Remdesivir, LPV/r, Interferon, HCQ | 3100 | MULTITHERAPY |
| CHI49088 | China | Severe | Hospital | Stem Cell, Ruxolitinib | 70 | MULTITHERAPY |
| NCT04326426 | United States | Severe | Hospital | Tradipitant | 300 | NEURO |
| NCT04343963 | Mexico | NA | Hospital | Pyridostigmine Bromide | 436 | NEUROGENIC |
| NCT04368156 | Spain | NA | Hospital | Vagus nerve stimulation | 90 | NEUROGENIC |
| NCT04346693 | Russia | NA | Hospital | Dalargin | 320 | OPIOID |
| CHI49342 | China | Non-severe | Unclear | Polyinosinic- Polycytidylic Acid | 40 | POLYNUCLEOTID |
| NL8491 | Netherlands | Severe | Hospital | Imatinib | 386 | PROTEIN KINASE INHIBITOR |
| EU/2020-001236-10/NL/ | Netherlands | Severe | Hospital | Imatinib mesilate | 304 | PROTEIN KINASE INHIBITOR |
| CHI49952 | China | NA | Outpatient | Psychological | 180 | PSYCHOLOGIC |
| NCT04342663 | United States | NA | Outpatient | Fluvoxamine | 152 | PSYCHOLOGIC |
| IR/47006 | Iran | NA | Hospital | Trifluoperazine, HCQ | 70 | PSYCHOLOGIC |
| NCT04326452 | United States | Severe | Hospital | Bidirectional oxygen | 15 | PULMONARY |
| IR/46969 | Iran | NA | Hospital | Bromhexine | 60 | PULMONARY |
| NCT04355364 | France | NA | ICU | Dornase Alfa Inhalation Solution | 100 | PULMONARY |
| CHI50910 | China | Severe | ICU | ECMO | 30 | PULMONARY |
| GERDRKS00021300 | Germany | Severe | Hospital | Ecmo | 30 | PULMONARY |
| IR/47173 | Iran | Unclear | Unclear | Formoterol | 50 | PULMONARY |
| NCT04325906 | United States | Severe | ICU | High nasal flow cannula | 346 | PULMONARY |
| EU/2020-001391-15/IE/ | Ireland | NA | Hospital | HUMAN ALPHA1-PROTEINASE INHIBITOR | 36 | PULMONARY |
| NCT04332081 | United States | NA | Hospital | Hyperbaric oxygen | 40 | PULMONARY |
| CHI49799 | China | NA | Unclear | Inhaled solution | 60 | PULMONARY |
| NCT04340414 | China | NA | Hospital | Low flow ECMO | 10 | PULMONARY |
| NCT04359251 | China | NA | Hospital | Mechanical Support | 20 | PULMONARY |
| NCT04344730 | France | NA | ICU | O2 support, Corticosteroids | 550 | PULMONARY |
| NCT04359862 | Spain | NA | Hospital, Unclear | Sedation | 50 | PULMONARY |
| NCT04359862 | Spain | NA | Hospital, Unclear | Sedation | 50 | PULMONARY |
| NCT04355026 | Slovenia | NA | Hospital | HCQ, Bromhexine | 90 | PULMONARY |
| NCT04336462 | China | Severe | Hospital | Hydrogen , oxygen | 100 | PULMONARY |
| NCT04344431 | France | NA | Hospital | Hyperbaric oxygen | 100 | PULMONARY |
| EU/2020-001329-30/AT/ | China | NA | ICU | Nitric oxide | 200 | PULMONARY |
| NCT04305457 | United States | Mixed | Hospital | Nitric Oxide | 240 | PULMONARY |
| NCT04306393 | United States | Severe | ICU | Nitric Oxide | 200 | PULMONARY |
| CHI49283 | China | Mixed | Hospital | Oxygen | 440 | PULMONARY |
| NCT04320056 | Canada | Severe | Hospital | Oxygen | 216 | PULMONARY |

| | | | | | | |
|---|---|---|---|---|---|---|
| CHI49747 | China | Mixed | Outpatient, Hospital | Ozone | 180 | PULMONARY |
| CHI49947 | China | Mixed | Outpatient, Hospital | Ozone | 60 | PULMONARY |
| CHI49737 | China | NA | Hospital | Ozone | 60 | PULMONARY |
| IR/47149 | Iran | NA | Unclear | Ozone Major Autohemotherapy | 80 | PULMONARY |
| NCT04359797 | United States | NA | Hospital | Prone positioning | 300 | PULMONARY |
| NCT04358939 | France | NA | Hospital | Prone positioning | 248 | PULMONARY |
| NCT04344106 | France | NA | Hospital, ICU | Prone positioning | 25 | PULMONARY |
| NCT04337541 | Denmark | Non-severe | Healthcare Workers, Outpatient | Surgical facial mask | 6000 | PULMONARY |
| NCT04331366 | United States | Mixed | Hospital | Bidirectional oxygen | 5 | PULMONARY |
| CHI48801 | China | Severe | Hospital, ICU | Pirfenidone | 292 | PULMONARY FIBROSIS RX |
| NCT04282902 | China | NA | Hospital | Pirfenidone | 294 | PULMONARY FIBROSIS RX |
| CHI51416 | China | NA | Unclear | Pirfenidone | 40 | PULMONARY FIBROSIS RX |
| CHI51118 | China | NA | Unclear | Pirfenidone | 40 | PULMONARY FIBROSIS RX |
| NCT04366791 | United States | NA | Hospital | Radiation | 10 | RADIATION |
| NCT04330300 | Ireland | NA | Healthy Unexposed | Antihypertensives | 2414 | RAS |
| NCT04364893 | Brazil | NA | Hospital | ARB and ACEi | 500 | RAS |
| NCT04329195 | France | NA | Hospital | Discontinuation of RAS | 554 | RAS |
| NCT04340557 | United States | NA | Hospital | Losartan | 200 | RAS |
| IR/46824 | Iran | Unspecified | Hospital | Losartan | 100 | RAS |
| NCT04312009 | United States | Severe | Hospital | Losartan | 200 | RAS |
| NCT04311177 | United States | Non-severe | Outpatient | Losartan | 580 | RAS |
| NCT04335123 | United States | Severe | Hospital, ICU | Losartan | 50 | RAS |
| NCT04355936 | Argentina | NA | Unclear | Telmisartan | 400 | RAS |
| NCT04335786 | Netherlands | Mixed | Hospital | Valsartan | 651 | RAS |
| CHI50341 | China | NA | Unclear | Physical rehabiliation | 80 | REHABILITATION |
| NCT04365738 | Turkey | NA | Outpatient | Respiratory coaching | 270 | REHABILITATION |
| CHI50973 | China | Severe | Hospital | Statin | 100 | SERINE PROTEASE INHIBITOR |
| ISRCTNISRCTN83971151 | Argentina | NA | Hospital | LPV/r, IFN, HCQ, remdesivir | 10000 | SOLIDARITY |
| JPjRCTs031190269 | Japan | Unspecified | Outpatient | Ciclesonide | 100 | STEROID |
| NCT04348305 | Denmark | Severe | Hospital, ICU | Corticosteroids | 1000 | STEROID |
| NCT04355637 | Spain | NA | Hospital | Corticosteroids | 300 | STEROID |
| NCT04343729 | Brazil | NA | Unclear | Corticosteroids | 420 | STEROID |
| NCT04331054 | France | NA | Hospital | Corticosteroids | 436 | STEROID |
| NCT04327401 | Brazil | Mixed | Unclear | Corticosteroids | 290 | STEROID |
| CHI50453 | China | NA | Outpatient, Hospital | Corticosteroids | 200 | STEROID |
| NCT04263402 | China | Severe | Unclear | Corticosteroids | 100 | STEROID |

| | | | | | | |
|---|---|---|---|---|---|---|
| NCT04344288 | France | NA | Hospital | Corticosteroids | 304 | STEROID |
| IR/46904 | Iran | NA | Hospital | Methylprednisolone | 40 | STEROID |
| IR/47088 | Iran | NA | ICU | Methylprednisolone | 40 | STEROID |
| NCT04325061 | Spain | Severe | Hospital | Corticosteroids | 200 | STEROIDS |
| IR/46776 | Iran | NA | Hospital | Corticosteroids | 48 | STEROIDS |
| NCT04355247 | Puerto Rico | NA | Hospital | Corticosteroids | 20 | STEROIDS |
| CHI48777 | China | Severe | Hospital | Corticosteroids | 48 | STEROIDS |
| NCT04244591 | China | Severe | ICU | Corticosteroids | 80 | STEROIDS |
| NCT04323592 | Italy | Severe | Hospital | Corticosteroids | 104 | STEROIDS |
| NCT04341038 | Spain | Severe | ICU | Corticosteroids, tacrolimus | 84 | STEROIDS |
| CHI49534 | China | Severe | Hospital | Alpha Lipoic Acid | 68 | SUPPLEMENT |
| IR/47139 | Iran | NA | Outpatient | Asafoetdida | 60 | SUPPLEMENT |
| IR/46868 | Iran | NA | Outpatient | Berberine | 40 | SUPPLEMENT |
| IR/47193 | Iran | NA | Hospital | Black myrobalan + Mastic + Sugarcane | 10 | SUPPLEMENT |
| IR/46875 | Iran | NA | Hospital | Calcifediol | 260 | SUPPLEMENT |
| IR/47010 | Iran | NA | Healthy Exposed, Healthcare Workers | Calcifediol | 540 | SUPPLEMENT |
| IR/46978 | Iran | NA | Outpatient | Crocetin | 40 | SUPPLEMENT |
| IR/46554 | Iran | NA | Hospital | Crostop/Croguard | 150 | SUPPLEMENT |
| IR/46879 | Iran | NA | Hospital | Herbal | 110 | SUPPLEMENT |
| IR/46913 | Iran | NA | Unclear | Herbal | 130 | SUPPLEMENT |
| IR/46828 | Iran | NA | Hospital | Herbal | 60 | SUPPLEMENT |
| IR/46850 | Iran | NA | Unclear | Herbal | 60 | SUPPLEMENT |
| IR/46907 | Iran | NA | Unclear | Herbal | 60 | SUPPLEMENT |
| IR/46958 | Iran | NA | Outpatient | Herbal | 40 | SUPPLEMENT |
| IR/46961 | Iran | NA | Hospital | Herbal | 15 | SUPPLEMENT |
| IR/47016 | Iran | NA | Hospital | Herbal | 60 | SUPPLEMENT |
| IR/46733 | Iran | NA | Hospital | Herbal medicine | 64 | SUPPLEMENT |
| IR/46893 | Iran | NA | Outpatient | Licorice | 40 | SUPPLEMENT |
| CHI50421 | China | Mixed | Outpatient, Hospital | Lipoic Acid | 394 | SUPPLEMENT |
| IR/46903 | Iran | NA | Hospital | Marshmallow + Licorice | 60 | SUPPLEMENT |
| IR/46963 | Iran | NA | ICU | Melatonin, Vitamin C | 20 | SUPPLEMENT |
| NCT04323345 | Egypt | NA | Unclear | Nutritional Support | 1000 | SUPPLEMENT |
| NCT04323514 | Italy | Severe | Hospital | Nutritional Support | 500 | SUPPLEMENT |
| IR/47251 | Iran | NA | Hospital | Pomegranate syrup | 66 | SUPPLEMENT |
| NCT04366180 | Spain | NA | Healthcare Workers | Probiotic | 314 | SUPPLEMENT |
| CHI49321 | China | Mixed | Outpatient, Hospital | Probiotics | 300 | SUPPLEMENT |

| | | | | | | |
|---|---|---|---|---|---|---|
| CHI49530 | China | Severe | Hospital | Regulating Intestinal Flora Agent | 60 | SUPPLEMENT |
| IR/47318 | Iran | NA | Hospital | Syrup zofa | 100 | SUPPLEMENT |
| IR/46974 | Iran | NA | Unclear | Vitamin A | 140 | SUPPLEMENT |
| NCT04264533 | China | Severe | ICU | Vitamin C | 140 | SUPPLEMENT |
| NCT04357782 | United States | NA | Hospital | Vitamin C | 20 | SUPPLEMENT |
| IR/46804 | Iran | NA | Hospital | Vitamin C | 60 | SUPPLEMENT |
| NCT04342728 | United States | Non-severe | Outpatient | Vitamin C, Zinc | 520 | SUPPLEMENT |
| NCT04344041 | France | NA | Unclear | Vitamin D | 260 | SUPPLEMENT |
| IR/46751 | Iran | Unspecified | Hospital | Vitaminc C | 40 | SUPPLEMENT |
| IR/46838 | Iran | NA | ICU | Vitamins | 60 | SUPPLEMENT |
| NCT04328441 | Netherlands | NA | Healthcare Workers | BCG Vaccine | 1500 | VACCINE |
| NCT04327206 | Australia | NA | Healthcare Workers | BCG Vaccine | 4170 | VACCINE |
| NCT04352608 | China | NA | Healthy Unexposed | Vaccine | 744 | VACCINE |
| EU/2020-001072-15/GB/ | United Kingdom | NA | Healthy Unexposed | Vaccine | 510 | VACCINE |
| NCT04283461 | United States | None | Healthy Unexposed | Vaccine | 105 | VACCINE |
| NCT04324606 | United Kingdom | None | Healthy Unexposed | Vaccine | 1112 | VACCINE |
| NCT04276896 | China | NA | Hospital | Vaccine | 100 | VACCINE |
| NCT04299724 | China | NA | Healthy Unexposed, Healthy Exposed, Outpatient | Vaccine | 100 | VACCINE |
| CURPCEC00000306-En | Cuba | NA | Healthy Exposed | Vaccine | 80 | VACCINE |
| NCT04336410 | United States | Non-severe | Healthy Unexposed | Vaccine | 40 | VACCINE |
| NCT04336410 | United States | Non-severe | Healthy Unexposed | Vaccine | 40 | VACCINE |

SUPPLEMENTARY TABLE 2. STUDIES WITH ANTIMALARIALS, LOPANOVIR/RITONAVIR, OR INTERFERONS. The setting of each study, whether hospital or outpatient, the type of control (AC: Active control, RCT: randomized control; soc: standard of care; PLAC: placebo control, whether treatment (TREAT) or prevention (PREV), the severity of illness, number of subjects, quarter study initiated, quarter study projects completion of enrollment, and duration of symptoms for patient inclusion are listed. Studies projecting completion of enrollment by the end of the second quarter of 2020 are bolded. Outpatient studies with planned completion by the end of the second quarter of 2020 are italicized.

| OUTPATIENT OR HOSPITAL | TYPE OF CONTROL | PREVENTION OR TREATMENT | SEVERITY OF ILLNESS | NO OF SUBJECTS | BEGIN DATE | PROPOSED END OF ENROLLMENT | DURATION SYMPTOMS |
|---|---|---|---|---|---|---|---|
| | | | | HCQ OR CHLOROQUINE | | | |
| OUT | RCT,PLAC | PREV (6) | HEALTHY, EXPOSED | 360,3500,440,400,350,1700 | Q1(20),Q2(20) | 3 Q3(20), 2 Q4(20), 1 Q2(21) | N/A |
| OUT | AC azithromycin, AC LPV/r | PREV (2) | HEALTHY, EXPOSED | 900,1200 | Q1(20),Q2(20) | 1 Q3(20, 1Q4(20) | N/A |
| OUT | RCT PLAC | PREV,TREAT | HEALTHY EXPOSED, MILD | 3000 | Q1(20) | ***Q2(20)*** | 4 |
| OUT | AC ascorbic acid | PREV | HEALTHY EXPOSED | 2000 | Q2(20) | Q3(20) | 4 |
| OUT | AC ascorbic acid | TREAT | MILD,MOD | 1250 | Q2(20) | Q3(21) | 2 |
| OUT | AC azithromycin | TREAT | MILD,MOD | 1550 | Q2(20) | Q1(21) | 7 |
| OUT | RCT PLAC | TREAT, PREV | MILD, HEALTHY EXPOSED | 3040 | Q1(20) | ***Q2(20)*** | 5 |
| OUT | RCT PLAC | TREAT | MILD | 210 | Q1(20) | NO DATE | 7 |
| OUT | MULTIDOSE PLAC | TREAT | MILD | 400 | Q2(20) | Q2(21) | ANY DUR |
| OUT | ac (azithromycin+hcq,hcq) | TREAT | MILD | 160 | Q2(20) | Q2(21) | ANY DUR |
| OUT | RCT PLAC | TREAT | MILD | 1660 | Q1(20) | Q3 (20) | 4 |
| OUT | AC (lpv/r) | TREAT | MILD | 150 | Q1(20) | ***Q2(20)*** | ANY DUR |
| MIXED | AC azithromycin | TREAT | MOD,SEV | 600 | Q2(20) | Q2(21) | 7 |
| MIXED | RCT PLAC | TREAT | MIXED | 210 | Q2(20) | Q3 (20) | ANY DUR |
| HOSP | AC azithromycin | TREAT (4) | MOD, SEV | 630;500;226;300 | Q2(20) | Q3,Q4(20) | ANY DUR |
| HOSP | AC, azithromycin | TREAT | SEV,CRIT | 440 | Q1(20) | Q3 (20) | ANY DUR |
| HOSP | RCT PLAC | TREAT | MILD,MOD | 300 | Q2(20) | Q4(20) | 3 |
| HOSP | RCT PLAC | TREAT | MIXED | 250 | Q1(20) | **Q2(20)** | 2 |
| HOSP | AC (resdemevir) | TREAT | MOD, SEV | 700 | Q1(20) | NO DATE | ANY DUR |
| HOSP | AC (lpv/r,losartan,PLAC) | TREAT | MOD, SEV | 4000 | Q1(20) | NO DATE | 3 |
| HOSP | AC (lpv/r,baricitinib,sarilumab,PLAC) | TREAT | MOD, SEV | 1000 | Q1(20) | Q1(21) | ANY DUR |

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| HOSP | AC (faviparavir) | TREAT | MOD, SEV | 150 | Q1(20) | Q1(21) | 14 |
| HOSP | RCT PLAC | TREAT | MOD, SEV | 202 | Q1(20) | **Q2(20)** | ANY DUR |
| HOSP | RCT PLAC | TREAT | MOD, SEV | 350 | Q2(20) | **Q2(20)** | 5 |
| HOSP | AC (faviparavir) | TREAT | SEV | 150 | Q1(20) | **Q2(20)** | 14 |
| HOSP | AC(chq,hcq) | TREAT | SEV | 100 | Q1(20) | Q2(21) | 14 |
| HOSP | RCT PLAC | TREAT | SEV | 510 | Q2(20) | Q3 (20) | 10 |
| HOSP | AC (azithromycin) | TREAT | SEV,CRIT | 276 | Q2(20) | Q3 (20) | 3 |
| HOSP | RCT PLAC | TREAT | SEV,CRIT | 1000 | Q2(20) | NO DATE | ANY DUR |
| HOSP | RCT PLAC | TREAT | CRIT | 500 | Q1(20) | Q4(20) | ANY DUR |
| HOSP | AC(high vs low dose HCQ) | TREAT | CRIT | 440 | Q1(20) | Q3 (20) | ANY DUR |
| HOSP | AC (hcq +/- famotidine) | TREAT | SEV | 1200 | Q2(20) | Q3 (20) | 1 |
| HOSP | RCT (PLAC) | TREAT | SEV | 220 | Q2(20) | Q1(21) | ANY DUR |
| HOSP | RCT (PLAC) | TREAT | SEV | 1300 | Q2(20) | Q3(20) | 2 |
| HOSP | RCT (PLAC) | TREAT | MIXED | 626 | Q2(20) | Q3 (20) | 3 |
| OUT | RCT(soc) | TREAT | MILD | 400 | Q2(20) | NO DATE | ANY DUR |
| | | | | LOPANOVIR/RITANOVIR | | | |
| OUT | AC HCQ | PREV (2) | HEALTHY | 1200,1220 | Q2(20) | ***Q2(20),***Q3(21) | N/A |
| OUT | AC HCQ | TREAT | MILD, MOD | 150 | 03/20/20 | ***Q2(20)*** | ANY DUR |
| Mixed | AC( Mulitple) | TREAT | MIXED | 500 | 04/20/20 | Q4(20) | ANY DUR |
| Mixed | AC (Ebastine) | TREAT | MIXED | 100 | 02/20/20 | Q1(20) | ANY DUR |
| Mixed | AC (Carrimycin) | TREAT | MIXED | 520 | 02/20/20 | Q1(21) | ANY DUR |
| Mixed | AC HCQ | TREAT | MIXED | 112 | 02/20/20 | Q4(20) | ANY DUR |
| Hosp | AC HCQ,losartan | TREAT | MOD,SEV | 4000 | 04/20/20 | Q1(21) | 3 |
| Hosp | AC HCQ IFN, STEROID | TREAT | SEV | 5000 | 02/20/20 | **Q2(20)** | ANY DUR |
| HOSP | RCT(soc) | TREAT | SEV | 160 | Q1(20) | Q1(21) | ANY DUR |
| HOSP | RCT (soc) | TREAT | MILD | 328 | Q1(20) | Q1(21) | 7 |
| | | | | INTERFERON | | | |
| OUT | AC (thymosin) | PREV | HEALTHY | 2944 | Q1(20) | ***Q2(20)*** | N/A |
| OUT | AC(chimed) | TREAT | MILD | 238 | Q1(20) | Q1(22) | Q2(22) |
| MIXED | RCT (soc) | TREAT | MIXED | 328 | Q1(20) | **Q2(20)** | 7 |
| MIXED | AC(ebastine) | TREAT | MIXED | 100 | Q1(20) | Q1(20) | ANY DUR |
| MIXED | AC (super compunded ifn) | TREAT | MIXED | 100 | Q1(20) | Q3 (20) | ANY DUR |
| MIXED | AC(ifn+umifenovir,umifenovir) | TREAT | MIXED | 100 | Q1(20) | **Q2(20)** | ANY DUR |
| HOSP | AC(lpv/r, hcq, steroids)) | TREAT | MIXED | 5000 | Q1(20) | Q2(21) | ANY DUR |
| HOSP | RCT (PLAC) | TREAT | MILD,MOD | 400 | Q1(20) | NO DATE | 1 |

| AGENT | HOSPITAL OR OUTPATIENT | TYPE OF CONTROL | TREAT OR PREVENT | SEVERITY | NUMBER SUBJECTS | BEGIN DATE | PROPOSED ENROLLMENT END | DISEASE DURATION |
|---|---|---|---|---|---|---|---|---|
| FAVIPIRAVIR | HOSP | RCT PLAC | TREAT | MIXED | 210 | Q2(20) | Q3 (20) | ANY DUR |
| | HOSP | ac (umifenovir) | TREAT | MIXED | 240 | Q1(20) | **Q2(20)** | 12 |
| | HOSP | AC(fvp, fvp combined with tociluzimab,soc) | TREAT | MIXED | 150 | Q1(20) | **Q2 (20)** | ANY DUR |
| | HOSP | AC (fvp, fvp combined with chloroquine,soc) | TREAT | MIXED | 150 | Q1(20) | Q3 (20) | ANY DUR |
| | HOSP | AC (fvp+hcq, lpv+hcq) | TREAT | MOD,SEV | 324 | Q2(20) | Q3 (20) | ANY DUR |
| UMIFENOVIR | OUT | RCT(PLAC) | TREAT | MILD | 380 | Q1(20) | Q4(20) | ANY DUR |
| | MIXED | AC(lpv/r) | TREAT | MIXED | 125 | COMPLETED | | ANY DUR |
| | MIXED | AC (azithromycin) | TREAT | MIXED | 100 | Q1(20) | **Q2(20)** | ANY DUR |
| | HOSP | AC(lpv/r, oseltamavir) | TREAT | MOD, SEV | 400 | Q1(20) | **Q2(20)** | ANY DUR |
| | HOSP | AC (umifenovir+hcq , hcq+lpv) | TREAT | MIXED | 200 | Q2(20) | Q3 (20) | ANY DUR |
| | HOSP | AC (umifenovir+hcq , hcq+lpv) | TREAT | MIXED | 100 | Q2(20) | Q3 (20) | ANY DUR |
| CAMOSTAT | MIXED | RCT (PLAC) | TREAT | MIXED | 580 | Q1(20) | Q4(20) | 2 |
| | HOSP | AC hcq+azithromycin, camostat+hcq,soc) | TREAT | MILD, MOD | 250 | Q2(20) | Q3 (20) | ANY DUR |
| EMITRICITABINE/TENOFOVIR | OUT | AC (hcq,PLAC) | PREV | HEALTHY | 4000 | Q2(20) | Q3 (20) | N/A |
| RIBAVIRIN | HOSP | AC (lpv/r+ifn b, ribavirin +lpv/r+ifn b) | TREAT | MILD, MOD | 108 | Q1(20) | Q1(21) | ANY DUR |
| REMDESIVIR | HOSP | AC(hcq+remdesivir, hcq) | TREAT | MIXED | 700 | Q1(20) | Q3 (20) | ANY DUR |
| TRIAZAVIRIN | HOSP | RCT (PLAC) | TREAT | MOD, SEV | 240 | Q1(20) | **Q2 (20)** | ANY DUR |
| IVERMECTIN | MIXED | RCT (soc) | TREAT | MIXED | 100 | Q2(20) | Q3 (20) | ANY DUR |

SUPPLEMENTARY TABLE 3: ANTIVIRAL AGENTS. The setting of each study, whether hospital or outpatient, the type of control (AC: Active control, RCT: randomized control; soc: standard of care; PLAC: placebo control, whether treatment (TREAT) or prevention (PREV), the severity of illness, number of subjects, quarter study initiated, quarter study projects completion of enrollment, and duration of symptoms for patient inclusion are listed. Studies projecting completion of enrollment by the end of the second quarter of 2020 are bolded. Outpatient studies with planned completion by the end of the second quarter of 2020 are italicized.

SUPPLEMENTARY TABLE 4: IMMUNE MODULATORS. The setting of each study, whether hospital or outpatient, the type of control (AC: Active control, RCT: randomized control; soc: standard of care; PLAC: placebo control, whether treatment (TREAT) or prevention (PREV), the severity of illness, number of subjects, quarter study initiated, quarter study projects completion of enrollment, and duration of symptoms for patient inclusion are listed. Studies projecting completion of enrollment by the end of the second quarter of 2020 are bolded.

| AGENT | HOSPITAL OR OUTPATIENT | TYPE OF CONTROL | TREAT OR PREVENT | SEVERITY | NUMBER SUBJECTS | BEGIN DATE | PROPOSED ENROLLMENT END | DISEASE DURATION |
|---|---|---|---|---|---|---|---|---|
| SARILUMAB | HOSP | RCT (PLAC) | TREAT | SEV,CRIT | 300 | Q1(20) | Q3 (20) | ANY DUR |
| | HOSP | RCT (PLAC) | TREAT | SEV,CRIT | 400 | Q1(20) | Q1(21) | ANY DUR |
| | HOSP | RCT (soc) | TREAT | SEV,CRIT | 460 | Q2(20) | NO DATE | ANY DUR |
| CD24F (blocks disinhibition of immune checkpoint) | HOSP | RCT (PLAC) | TREAT | SEV | 230 | Q1(20) | Q2(21) | ANY DUR |
| COLCHICINE | OUT | RCT (PLAC) | TREAT | MILD | 6000 | Q1(20) | Q3 (20) | 1 |
| | HOSP | RCT (soc) | TREAT | SEV | 2500 | Q2(20) | Q3 (20) | ANY DUR |
| IFX1 (monoclonal ab to complement) | HOSP | RCT (PLAC) | TREAT | SEV | 130 | Q1(20) | NO DATE | 14 |
| SELINEXOR | HOSP | RCT (PLAC) | TREAT | SEV | 230 | Q2(20) | Q3 (20) | ANY DUR |
| SILTUXIMAB | HOSP | AC (methlyprednisolone) | TREAT | SEV,CRIT | 200 | Q2(20) | **Q2 (20)** | ANY DUR |
| TOCILIZUMAB | MIXED | AC (azithromycin + hcq) | TREAT | SEV | 276 | Q2(20) | Q3 (20) | ANY DUR |
| | HOSP | AC sarilumab) | TREAT | SEV | 200 | Q1(20) | Q2(21) | ANY DUR |
| | HOSP | RCT (soc) | TREAT | SEV,CRIT | 188 | Q1(20) | **Q2(20)** | ANY DUR |
| | HOSP | RCT(PLAC) | TREAT | CRIT | 330 | Q1(20) | **Q2(20)** | ANY DUR |
| | HOSP | RCT(PLAC) | TREAT | CRIT | 100 | Q2(20) | Q3(20) | ANY DUR |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | HOSP | AC (anakinra, siltuximab, PLAC) | TREAT | CRIT | 342 | Q2(20) | Q3(20) | ANY DUR |
| | HOSP | RCT (PLAC) | TREAT | MIXED | 180 | Q2(20) | Q2(22) | ANY DUR |
| LENZILUMAB | HOSP | RCT (PLAC) | TREAT | MOD,SEV | 238 | Q2(20) | Q3 (20) | ANY DUR |
| TJ003234<br>anti-GM-CSF monoclonal ab | HOSP | RCT (PLAC) | TREAT | SEV,CRIT | 144 | Q2(20) | Q3 (20) | ANY DUR |
| THYMOSIN | HOSP | AC(PD-1) | TREAT | SEV | 120 | Q1(20) | Q1(21) | ANY DUR |
| CM4620<br>CRAC channel inhibitor | HOSP | RCT (soc) | TREAT | SEV | 144 | Q2(20) | Q3 (20) | ANY DUR |
| LERONLIMAB | HOSP | RCT (PLAC) | TREAT | SEV,CRIT | 390 | Q2(20) | Q4(20) | ANY DUR |
| ECULIZIMAB | HOSP | RCT soc) | TREAT | SEV,CRIT | 120 | Q2(20) | Q3 (20) | ANY DUR |
| CYTOKINE PROTEIN | HOSP | RCT (soc) | TREAT | MIXED | 480 | Q1(20) | **Q2(20)** | 8 |
| AVDORALIMAB | HOSP | RCT (PLAC) | TREAT | SEV,CRIT | 108 | Q2(20) | Q3 (20) | ANY DUR |

SUPPLEMENTARY TABLE 5: OTHER AGENTS. The interventions are listed by class. The setting of each study, whether hospital or outpatient, the type of control (AC: Active control, RCT: randomized control; soc: standard of care; PLAC: placebo control, whether treatment (TREAT) or prevention (PREV), the severity of illness, number of subjects, quarter study initiated, quarter study projects completion of enrollment, and duration of symptoms for patient inclusion are listed. Studies projecting completion of enrollment by the end of the second quarter of 2020 are bolded. Outpatient studies with planned completion by the end of the second quarter of 2020 are italicized.

| TREATMENT | OUTPATIENT OR HOSPITAL | TYPE OF CONTROL | TREAT OR PREVENT | SEVERITY | NUMBER SUBJECTS | BEGIN DATE | PROPOSED END ENROLLMENT | DURATION SYMPTOMS |
|---|---|---|---|---|---|---|---|---|
| | | | | **IMMUNE GLOBULIN** | | | | |
| CONVALESCENT PLASMA | MIXED | RCT PLAC | TREAT | MIXED | 500 | Q2(20) | Q2(21) | 14 |
| | HOSP | RCT (soc) | TREAT | MIXED | 426 | Q2(20) | Q3 (20) | 4 |
| | HOSP | RCT (soc) | TREAT | MIXED | 278 | Q2(20) | Q3 (20) | 12 |
| | HOSP | RCT (soc) | TREAT | SEV | 200 | Q1(20) | Q1(21) | 3 |
| | HOSP | RCT (soc) | TREAT | SEV,CRIT | 100 | Q1(20) | **Q2(20)** | ANY DUR |
| IVIG | HOSP | RCT (PLAC) | TREAT | SEV,CRIT | 138 | Q2(20) | Q3 (20) | ANY DUR |
| | | | | **CELL THERAPY** | | | | |
| STEM CELL | OUT | RCT(PLAC) | PREV | HEALTHY | 100 | Q2(20) | Q4(20) | N/A |
| | MIXED | Case control | TREAT | MIXED | 200 | Q1(20) | Q4(21) | ANY DUR |
| | HOSP | RCT(PLAC) | TREAT | SEV | 120 | Q1(20) | Q2(20) | ANY DUR |
| | | | | **CARDIOVASCULAR** | | | | |
| DISCONTINUATION OF RAS | HOSP | AC (continue or discontinue RAS) | TREAT(2) PREV(1) | MIXED, HEALTHY | 554;500;2414 | Q2(20),Q1(20) | Q3 (20);Q4(20);Q1(21) | ANY DUR, N/A |
| LOSARTAN | MIXED | RCT (soc) | TREAT | MIXED | 100 | COMPLETED | | |
| | OUT | RCT (soc) | TREAT | MILD,MOD | 200 | Q2(20) | Q3 (20) | ANY DUR |
| | OUT | RCT (soc) | TREAT | MILD,MOD | 580 | Q2(20) | Q2(21) | 3 |
| | HOSP | RCT (soc) | TREAT | SEV,CRIT | 200 | Q2(20) | Q2(21) | ANY DUR |
| TELMISARTAN | HOSP | RCT(soc) | TREAT | MIXED | 400 | Q2(20) | Q3 (20) | ANY DUR |
| VALSARTAN | HOSP | RCT (PLAC) | TREAT | MOD | 651 | Q2(20) | Q3 (20) | 1 |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| AMIODARONE | HOSP | AC(verapamil) | TREAT | MIXED | 804 | Q2(20) | Q1(21) | ANY DUR |
| | | | | **PULMONARY TREATMENT** | | | | |
| PIRFENIDONE | MIXED | RCT (soc) | TREAT | MIXED | 294 | Q1(20) | **Q2(20)** | 7 |
| | HOSP | RCT (soc) | TREAT | SEV,CRIT | 292 | Q1(20) | Q3(20) | 14 |
| HYPERBARIC OXYGEN | HOSP | RCT (soc) | TREAT | MIXED | 100 | Q2(20) | Q2(21) | ANY DUR |
| INHALED NITRIC OXIDE | HOSP | RCT(soc) | TREAT | MIXED | 240 | Q1(20) | Q2(21) | ANY DUR |
| | HOSP | RCT(soc) | TREAT | SEV,CRIT | 200 | Q1(20) | Q2(21) | ANY DUR |
| DORNASE ALFA (cystic fibrosis agent) | HOSP | RCT (soc) | TREAT | CRIT | 100 | Q2(20) | Q4(20) | ANY DUR |
| PRONE POSITION | HOSP | AC(supine) | TREAT(2) | CRIT; MIXED | 248;300 | Q2(20) | Q4(20); Q1(21) | ANY DUR |
| OZONE | HOSP | RCT (soc) | TREAT | MIXED | 180 | Q1(20) | **Q2 (20)** | 7 |
| OXYGEN/HYDROGEN | HOSP | AC (oxygen) | TREAT(2) | MOD,SEV | 100;440 | Q1(20) | Q3 (20) | ANY DUR |
| SURGICAL FACE MASK | OUT | AC(face mask or none) | PREV | HEALTHY | 6000 | Q2(20) | Q3 (20) | N/A |
| CLOSED LOOP OXYGEN | HOSP | AC (normal O2 delivery vs closed loop) | TREAT | MOD,SEV | 216 | Q2(20) | Q4(20) | ANY DUR |
| RESPIRATORY COACHING | MIXED | RCT (soc) | TREAT | MILD,MOD | 270 | Q1(20) | Q3 (20) | ANY DUR |
| | | | | **ONCOLOGIC AGENTS** | | | | |
| IMATINIB | HOSP | RCT (PLAC) | TREAT(2) | SEV | 304;386 | Q1(20) | **Q2 (20)** | ANY DUR |
| LY3127804 | HOSP | RCT (PLAC) | TREAT | MIXED | 200 | Q2(20) | Q3 (20) | ANY DUR |
| BEVACIZUMAB | HOSP | RCT (soc) | TREAT | SEV,CRIT | 140 | Q1(20) | **Q2(20)** | ANY DUR |
| | | | | **METABOLIC AGENTS** | | | | |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| METFORMIN | HOSP | RCT (soc) | TREAT | MIXED | 200 | Q1(20) | **Q2 (20)** | ANY DUR |
| DAPLIGLIFLOZIN | HOSP | RCT (PLAC) | TREAT | MILD,MOD | 900 | Q2(20) | Q4(20) | 3 |
| ESTRADIOL | OUT | RCT (soc) | TREAT | MILD,MOD | 110 | Q2(20) | Q4(20) | 7 |
| ATORVASTATIN | MIXED | RCT (soc) | TREAT | MIXED | 100 | Q2(20) | NO DATE | ANY DUR |
| MEDIUM CHAIN TG | OUT | RCT (soc) | TREAT | MILD | 120 | Q2(20) | *Q2 (20)* | ANY DUR |
| | | | | **SUPPLEMENTS** | | | | |
| ECHINACEA AND GINGER | OUT | RCT (soc) | TREAT | MILD | 100 | Q2(20) | ***Q2 (20)*** | ANY DUR |
| VITAMIN D | MIXED | AC (200,000 IU vs 50,000 IU), RCT(soc) | TREAT(3) | MILD,MOD | 260;260;540 | Q2(20) | Q3 (20), Q4(20) | 3, ANY DUR |
| ASCORBIC ACID | HOSP | RCT (PLAC) | TREAT | CRIT | 140 | Q1(20) | Q3 (20) | ANY DUR |
| ASCORBIC ACID, ZINC | OUT | AC(ascorbic acid, zinc, soc) | TREAT | MILD | 520 | Q2(20) | Q3 (20) | ANY DUR |
| LIPOIC ACID | OUT | RCT (soc) | TREAT | MIXED | 394 | Q1(20) | ***Q2 (20)*** | ANY DUR |
| PROBIOTICS | HOSP;OUT | RCT (soc);RCT(PLAC) | TREAT;PREV | MIXED;HEALTHY | 300;314 | Q1(20);Q2(20) | Q3 (20) | ANY DUR |
| NATURAL HONEY | MIXED | RCT (soc) | TREAT | MIXED | 1000 | Q1(20) | Q4(20) | ANY DUR |
| ESCIN | HOSP | RCT (soc) | TREAT | MIXED | 120 | Q1(20) | **Q2 (20)** | ANY DUR |
| Crostop/Croguard | MIXED | RCT (soc) | TREAT | MIXED | 150 | Q1(20) | **Q2 (20)** | ANY DUR |
| VITAMIN A | MIXED | RCT (soc) | TREAT | MIXED | 140 | Q2(20) | NO DATE | ANY DUR |
| | | | | **NEUROGENIC** | | | | |
| TRADIPITANT | HOSP | RCT (PLAC) | TREAT | SEV,CRIT | 300 | Q2(20) | Q3 (20) | ANY DUR |

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| PYRIDOSTIGMINE | HOSP | RCT (PLAC) | TREAT | SEV | 436 | Q2(20) | Q2(21) | ANY DUR |
| VAZEGEPANT | HOSP | RCT (PLAC) | TREAT | SEV | 120 | Q2(20) | Q3 (20) | ANY DUR |
| | | | | **PSYCHOLOGICAL** | | | | |
| FLUVOXAMINE | OUT | RCT (PLAC) | TREAT | MILD | 152 | Q2(20) | Q3 (20) | ANY DUR |
| PSYCHOLOGICAL THERAPY | MIXED | RCT (soc) | TREAT | MIXED | 180 | Q1(20) | Q1(22) | ANY DUR |
| | | | | **GLUCOCORTICOIDS** | | | | |
| METHYLPREDNISOLONE | HOSP | AC (high vs low dose) | TREAT | SEV | 100 | Q1(20) | Q2 (20) | ANY DUR |
| CORTICOSTEROID | MIXED | AC (early vs late vs no steroid) | TREAT | MIXED | 200 | Q1(20) | Q2 (20) | ANY DUR |
| DEXAMETHASONE | HOSP | RCT (soc) | TREAT(2) | CRIT | 290;200 | Q2(20) | Q3 (20),Q4(20) | 1,ANY DUR |
| CICLESONIDE | HOSP | RCT (PLAC) | TREAT | SEV | 120 | Q2(20) | Q3 (20) | ANY DUR |
| SYMBICORT | HOSP | RCT (soc) | TREAT | MIXED | 436 | Q2(20) | Q3 (20) | 2 |
| | | | | **ANTICOAGULATION** | | | | |
| ASPIRIN | MIXED | RCT (soc) | TREAT | MIXED | 128 | Q1(20) | Q2 (20) | ANY DUR |
| LOW MOLECULAR WEIGHT HEPARIN | HOSP | AC(lmw vs mechanical VTE prev) | PREV | MIXED | 120 | Q1(20) | Q2 (20) | ANY DUR |
| DEFIBROTIDE | HOSP | RCT (PLAC) | TREAT | SEV,CRIT | 120 | Q2(20) | Q3 (20) | ANY DUR |
| ULINASTATIN | MIXED | RCT (soc) | TREAT | MIXED | 100 | Q1(20) | Q2 (20) | ANY DUR |

| COUNTRY | NAME | PROGRESS | NUMBER SUBJECTS | TYPE OF VACCINE | DATE BEGUN | COMPLETION DATE |
|---|---|---|---|---|---|---|
| United Kingdom | | PHASE I/11 | 510,1090 | attenuated adenovirus expressing spike protein | Q1(20) | ongoing |
| China | PicoVacc | PHASE I/11 | 744 | inactivated coronavirus | Q2(20) | Q4(21) |
| China | | PHASE I/11 | 100 | lentiviral vector | Q1(20) | Q3(23) |
| United States | mRNA-1273 | PHASE I/11 | 105 | Lipid nanoparticle (LNP) dispersion containing an mRNA that encodes for the prefusion stabilized spike protein 2019-nCoV. | Q1(20) | Q3(21) |
| China | Ad5-nCoV | PHASE II | 500 | Adenovirus vector recombinant vaccine | Q1(20) | Q1(21) |
| United States | INO-4800 | PHASE 1 | 40 | DNA vaccine with electroporation | Q2(20) | Q2(21) |
| Netherlands | | RCT(PLAC) | 1500 | BCG Vaccination | Q1(20) | Q4(20) |
| Australia | | RCT(PLAC) | 4170 | BCG Vaccination | Q1(20) | Q4(20) |
| China | | PHASE I | | Inactivated alum vaccine | Q2(20) | ongoing |
| Russia | Ad5 and Ad26 | PHASE I | 76 | Ad5 and Ad26 Vectored Vaccines | Q2(20) | ongoing |

SUPPLEMENTARY TABLE 6: VACCINES. The country of origin of each vaccine is listed, with name if established, the number of subjects currently being tested, the type of vaccine, the quarter study initiated, and the quarter and year study projects completion

| TRIAL REGISTRATION | COUNTRY | DATE COMPLETED | TYPE TRIAL | SETTING | NUMBER SUBJECTS | TREATMENT |
|---|---|---|---|---|---|---|
| IRCT20171105037262N4 | Iran | 2020-Jul | RCT | HOSP | 100 | adalimumab, HCQ background |
| CHICTR2000032456 | China | 2020-May | RCT | HOSP | 100 | Alter therapy |
| IRCT20200506047319N1 | Iran | 2020-Jul | RCT | HOSP | 100 | Alter therapy |
| IRCT20200610047722N1 | Iran | 2020-Jul | RCT | HOSP | 100 | Alter therapy |
| IRCT20080901001165N48 | Iran | 2020-Jul | RCT | HOSP | 100 | Alter Therapy |
| IRCT20200402046923N1 | Iran | 2020-May | RCT | HOSP | 110 | Alter Therapy |
| IRCT20200316046792N1 | Iran | 2020-May | RCT | HOSP | 150 | Alter therapy |
| IRCT20200411047016N1 | Iran | 2020-Jun | RCT | HOSP | 150 | Alter Therapy |
| IRCT20190418043307N1 | Iran | 2020-Jun | RCT | HOSP | 100 | Alter therapy, HCQ background |
| IRCT20200504047298N1 | Iran | 2020-Jun | RCT | HOSP | 100 | Atazanovir/ritonavir vs LPV/r |
| NCT04323527 | Brazil | 2020-May | RCT | HOSP | 278 | chloroquine |
| IRCT20200418047126N1 | Iran | 2020-Jun | RCT | HOSP | 100 | Colchicine, HCQ background |
| IRCT20200525047562N1 | Iran | 2020-Jul | OBS | HOSP | 100 | Conv Plasma |
| IRCT20080901001165N58 | Iran | 2020-Jun | RCT | HOSP | 100 | Conv Plasma |
| IRCT20150808023559N20 | Iran | 2020-Jul | RCT | HOSP | 100 | FPV + HCQ, HCQ + LPV/r |
| CHICTR2000030254 | China | NA | RCT | HOSP | 240 | FPV vs Umifenovir |
| NCT04343092 | Iraq | 2020-May | RCT | HOSP | 100 | HCQ |
| IRCT20200318046812N1 | Iran | 2020-Jun | RCT | HOSP | 324 | HCQ + FPV, HCQ + LPV/r |
| NCT04321278 | Brazil | 2020-Jun | RCT | HOSP | 440 | HCQ vs HCQ +AZT |
| IRCT20200317046797N3 | Iran | 2020-Jul | RCT | HOSP | 100 | IVIG, background HCQ, LPV/r |
| IRCT20160316027081N1 | Iran | 2020-Apr | RCT | HOSP | 374 | licorice |
| IRCT20180802040678N4 | Iran | 2020-Apr | RCT | HOSP | 100 | Losartan vs Amlodipine |
| CHICTR2000029308 | China | 2021-Jan | RCT | HOSP | 160 | LPV/r |
| NCT04276688 | Hong Kong | 2020-Mar | RCT | HOSP | 127 | LPV/r vs LPV/r +IFN |
| IRCT20160310026998N11 | Iran | 2020-Apr | RCT | HOSP | 200 | metformin |
| NCT04280705 | United States | 2020-May | RCT | HOSP | 1062 | Remdesivir |
| NCT04292730 | United States | 2020-Apr | RCT | HOSP | 1113 | Remdesivir |
| NCT04292899 | United States | 2020-Apr | RCT | HOSP | 4891 | Remdesivir |
| IRCT20190727044343N2 | Iran | 2020-Apr | RCT | HOSP | 100 | Statins |
| NCT04473170 | United Arab Emirates | 2020-May | RCT | HOSP | 146 | Stem cells |
| IRCT20151227025726N15 | Iran | 2020-Jul | RCT | HOSP | 100 | Umifenovir vs LPV/r |
| IRCT20200325046859N2 | Iran | 2020-Jun | RCT | HOSP | 100 | Umifenovir, HCQ background |
| IRCT20200322046833N1 | Iran | 2020-Apr | RCT | HOSP | 100 | Umifenovir, HCQ, LPV/r background |

| | | | | | | |
|---|---|---|---|---|---|---|
| IRCT20200324046850N1 | Iran | 2020-Jul | RCT | HOSP | 100 | Vitamin D vs acetylcysteine |
| NCT04320615 | United States | 2020-Jul | RCT | HOSP | 450 | tocilizumab |
| IRCT20200404046934N1 | Iran | 2020-Apr | RCT | MIXED | 130 | Alter therapy |
| CHICTR2000029434 | China | 2020-Dec | RCT | MIXED | 240 | Chi Med |
| CHICTR2000029433 | China | 2020-Dec | RCT | MIXED | 240 | Chi Med |
| CHICTR2000029559 | China | 2020-Feb | RCT | MIXED | 300 | HCQ |
| CHICTR2000029868 | China | 2020-Jun | RCT | MIXED | 360 | HCQ |
| IRCT20160625028622N1 | Iran | 2020-Apr | OBS | MIXED | 125 | Noscapine |
| IRCT20200410047009N1 | Iran | 2020-Jul | RCT | MIXED | 101 | NSAIDS |
| IRCT20180520039738N2 | Iran | 2020-Apr | RCT | MIXED | 140 | Vitamin A |
| IRCT20131129015584N2 | Iran | 2020-Jun | RCT | OUTPATIENT | 152 | Alter Theapy |
| IRCT20200508047345N1 | Iran | 2020-Jun | OBS | OUTPATIENT | 100 | Alter therapy |
| IRCT20200415047089N1 | Iran | 2020-May | RCT | OUTPATIENT | 100 | Alter Therapy |
| NCT04342650 | Brazil | 2020-May | RCT | OUTPATIENT | 152 | Chloroquine |
| NCT04365738 | Turkey | 2020-Apr | RCT | OUTPATIENT | 270 | Education |
| NCT04349241 | Egypt | 2020-Jun | RCT | OUTPATIENT | 100 | Favipiravir |
| NCT04304053 | Spain | 2020-Jun | RCT | OUTPATIENT | 2300 | HCQ |
| IRCT20160313027033N2 | Iran | 2020-May | RCT | OUTPATIENT | 120 | Interm Chain triglycerides |
| IRCT20200408046987N1 | Iran | 2020-Jun | RCT | OUTPATIENT | 125 | Ivermectin |
| IRCT20200503047280N1 | Iran | 2020-Jul | RCT | PREV | 300 | Alter Therapy |
| CHICTR2000029479 | China | 2020-May | RCT | PREV | 20000 | Chi Med |
| NCT04337541 | Denmark | 2020-Jun | RCT | PREV | 6000 | Facial Masks |
| NCT04408456 | India | 2020-Jul | OBS | PREV | 325 | HCQ |
| IRCT20190122042450N4 | Iran | 2020-Jun | RCT | PREV | 1000 | HCQ |
| NCT04308668 | United States | 2020-May | RCT | PREV | 1309 | HCQ |
| IRCT20200513047426N1 | Iran | 2020-Jul | RCT | PREV | 500 | HCQ |
| IRCT20140428017469N1 | Iran | 2020-Jul | OBS | PREV | 130000 | oral polio vaccine |

SUPPLEMENTARY TABLE 7: COMPLETED TRIALS AS OF SEPTEMBER 1, 2020. RCT: Randomized control trial. OBS: Observational. Setting is characterized as HOSP: Hospitalized, OUTPATIENT, or MIXED, or PREV:prevention study. The registration for each trial is given as is the country where registered, and the date of completion of enrollment